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Biodegradable polymers are inter-
esting materials in drug delivery as 
they are eliminated from the body 
without a second operation to remove 
them. In this study novel biodegrad-
able polymers, 2,2-bis(2-oxazoline) 
linked poly(ε-caprolactone) (PCL-O) 
and pegylated poly(lactic acid) linked 
with biotin (biotin-PEG-PLA), were 
developed for controlled and targeted 
pharmaceutical applications. Results 
indicate that PCL-O polymers are 
biocompatible and safe materials dis-
playing enzyme sensitive surface ero-
sion and biotinylated PLA-PEG nano-
particles enhance cancer therapy.
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ABSTRACT 
 
Research in the area of biodegradable polymers has attracted much attention during recent 
decades. After first establishing their position in reconstructive surgery (e.g. as suture 
materials) biodegradable polymers have entered a new era in drug delivery. They have 
become widely used materials in the delivery of anti-cancer drugs, peptides, proteins and 
hormones. The major advantage of biodegradable polymers is their property to degrade 
into non-toxic products which are eliminated from the body without the need to physically 
remove them after application. 
The objective of the present study was to develop novel biodegradable polymers for 
controlled and targeted pharmaceutical applications. Thus, novel 2,2-bis(2-oxazoline) 
linked poly(ε-caprolactone) (PCL-O) and pegylated poly(lactic acid) linked with biotin 
(biotin-PEG-PLA) were studied. The focus of this study was on the degradation 
mechanisms and a toxicity evaluation in the case of PCL-O. Biotin-PEG-PLA was prepared 
in the form of nanoparticles with an anticancer drug and the efficacy of avidin-biotin based 
cancer targeting was evaluated in vitro. 
PCL-O polymers were synthesized by using -caprolactone precursors with different 
molecular weights (Mn: 1500, 3900, 7500 and 12 000 g/mol). Poly(ε-caprolactone) (PCL) and 
PCL-O films were incubated (22 days) in phosphate buffer solution in the presence of 
pancreatin (1%, pH 7.5). Surface erosion of the PCL-O films occurred, and the erosion of the 
PCL-O films increased in parallel with a decrease in the PCL block length. The presence of 
lipase inhibitors delayed the weight loss of the PCL-O films. The enzymatic degradation of 
the polymer produced a wide variety of water soluble oligomers which were effectively 
separated and identified by HPLC-ESI-MSn. According to these results, ester bonds seem to 
be most sensitive to enzymatic degradation and correspondingly, pancreatic lipase appears 
to be mainly responsible for the enzymatic erosion of the PCL-O films. In vivo degradation, 
erosion (weight loss) and toxicity of PCL-O discs were evaluated after their subcutaneous 
implantation in Wistar rats for 1, 4 and 12 weeks. The in vivo evaluation demonstrated that 
PCL-O polymers had been biocompatible and were safe, enzyme-sensitive biomaterials. 
Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and 
avidin-biotin technology was evaluated in vitro as a way of enhancing the delivery of 
paclitaxel. Biotinylated nanoparticles (mean size ~110 nm) were targeted in vitro to brain 
tumor (glioma) cells (BT4C) by three-step avidin-biotin technology using transferrin as the 
targeting ligand. The three-step targeting procedure increased significantly the anti-
tumoral activity of paclitaxel when compared to the commercial paclitaxel formulation 
Taxol® and non-targeted nanoparticles. 
In conclusion, novel biodegradable polymers were developed for biomedical and 
pharmaceutical applications: PCL-O polymers show enzyme sensitive surface erosion 
properties and biocompatibility and biotinylated PLA-PEG nanoparticles could enhance 
cancer therapy. 
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TIIVISTELMÄ  
 
Biohajoavien polymeerien tutkimus on saanut paljon huomiota viimeisten 
vuosikymmenten aikana. Biohajoavat polymeerit ovat olleet pitkään käytössä korjaavan 
kirurgian sovelluksissa, mutta ne ovat aloittaneet myös uuden aikakauden lääkeaineiden 
annostelussa. Biohajoavista polymeereistä on tullut laajasti käytettyjä materiaaleja 
syöpälääkkeiden, peptidien, proteiinien ja hormonien annostelussa. Biohajoavien 
polymeerien suurimpana etuna voidaan pitää niiden hajoamista turvallisiksi tuotteiksi, 
joten niitä ei tarvitse poistaa annostelun jälkeen.  
Työn tarkoituksena oli kehittää uusia biohajoavia polymeerejä kontrolloituun ja 
kohdennettuun lääkeannosteluun. Työssä tutkittiin 2,2-bis(2-oksatsoliinilla)-linkattuja poly-
ε-kaprolaktoni (PCL-O) polymeerejä sekä biotiini-linkattua pegyloitua polymaitohappoa 
(biotiini-PEG-PLA). Työn päätarkoituksena oli arvioida PCL-O:n hajoamismekanismeja ja 
turvallisuutta. Lisäksi valmistettiin syöpälääkettä sisältäviä biotiini-PEG-PLA-
nanopartikkeleita ja tutkittiin niiden kohdentumista avidiini-biotiini-menetelmän avulla in 
vitro. 
PCL-O-polymeerit syntetisoitiin käyttämällä erikokoisia ε-kaprolaktonin esipolymeerejä 
(Mn: 1500, 3900, 7500 and 12 000 g/mol). Polykaprolaktoni- (PCL) ja PCL-O-filmejä 
inkuboitiin pankreatiinia sisältävässä (1 %) fosfaattipuskurissa (pH 7,5) 22 päivän ajan. 
PCL-O-filmien pintaeroosio havaittiin inkuboinnin aikana ja eroosionopeus oli sitä 
nopeampi mitä lyhyemmistä esipolymeereista ne oli valmistettu. Lipaasi-inhibiittorit 
hidastivat PCL-O-filmien painon laskua. Polymeerien entsymaattinen hajoaminen tuotti 
suuren määrän vesiliuokoisia oligomeerejä, jotka saatiin tehokkaasti eroteltua ja 
määritettyä uudella HPLC-ESI-MSn -menetelmällä. Saatujen tulosten perusteella näyttää 
siltä, että PCL-O:n esterisidokset olivat herkimpiä entsymaattiselle hajoamiselle. Tämän 
hajoamisen aiheutti todennäkoisesti pankreatiinin sisältämä lipaasientsyymi. Lisäksi      
PCL-O-kiekkojen hajoaminen, eroosio ja turvallisuus tutkittiin Wistar -rotilla 1, 4 ja 12 
viikon kuluttua ihon alaisesta implantoinnista. In vivo -kokeen tulokset vahvistivat, että 
PCL-O-polymeerit ovat bioyhteensopivia ja turvallisia entsyymisensitiivisiä 
biomateriaaleja.   
Paklitakselia sisältävien biotinyloitujen PLA-PEG-nanopartikkelien syöpäkohdennusta 
tutkittiin kolmivaiheisella kohdennusmenetelmällä in vitro. Biotinyloidut nanopartikkelit 
(koko ~110 nm) kohdennettiin BT4C-aivokasvainsoluihin (gliooma) kolmivaiheisen 
avidiini-biotiini–teknologian avulla käyttämällä transferriiniä kohdentimena. 
Kohdennusmenetelmä lisäsi merkittävästi paklitakselin tehoa kaupalliseen paklitakseliin 
(Taxol®) ja kohdentamattomiin nanopartikkeleihin verrattuna.  
Yhteenvetona voidaan todeta, että työssä kehitettiin uusia biohajoavia polymeerejä 
biolääketieteellisiin ja farmaseuttisiin sovelluksiin: PCL-O-polymeerit ovat 
entsyymisensitiivisiä ja bioyhteensopivia biomateriaaleja. Vastaavasti biotinyloidut PLA- 
PEG-nanopartikkelit voivat lisätä syöpähoidon tehoa. 
 
Luokitus: QT 37, QU 55.4, QU 135, QU 143, QU 195, QV 785, QZ 380, 
Yleinen Suomalainen asiasanasto: avidiini; biohajoaminen; lääkeaineet – kohdentaminen; lääkeaineet – 
annostelu; nanohiukkaset; polymeerit; polyesteri; syöpäsolut 
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1 Introduction  
Polymers are macromolecules consisting of repeating monomer units. Each polymer has 
unique properties depending on the structure and combination of the monomers in the 
polymer chain. Polymers have become part of our daily lives in many forms, perhaps the 
best known are plastic goods because of their ease of tailoring and processing have almost 
innumerable applications. Biodegradable polymers have been widely utilized in various 
commercial biomedical and pharmaceutical applications because they are able to degrade 
in the body due to the presence of susceptible chemical bonds. One major advantage of 
biodegradable polymers is that they can be applied without the need for removing them 
after use. Medical biodegradable polymers degrade in the body to non-toxic monomers 
which are completely eliminated from the body. Biodegradable polymers can be either of 
natural origins or they can be synthesized using advanced polymer chemistry. 
Synthetic polymers are preferred for many applications when compared to natural 
polymers since they can be synthesized with a precise batch to batch structure with the 
desired properties. Aliphatic polyesters, such as polyglycolic acid (PGA), polylactic acid 
(PLA) and poly-ε-caprolactone (PCL), were the first synthetic polymers to be utilized in the 
body as biodegradable suture materials (Brannon-Peppas and Vert 2000; Ueda and Tabata 
2003). Thereafter, aliphatic polyesters have been employed in various controlled release 
applications because they are able to extend drug release from days up to several months. 
At present, many sustained release products based on aliphatic polyesters are on the 
market for delivering a wide variety of substances such as peptides, proteins, hormones 
and small anticancer drugs in the forms of implants and microparticles (Wischke and 
Schwendeman 2008). Furthermore, they have been successfully tested in vaccine (O’Hagan 
et al. 2004; Peek et al. 2007) and DNA delivery (Panyam and Labhasetwar 2003; Chen et al. 
2007; Ramgopal et al. 2008). In addition, nanotechnological drug targeting have been 
extensively investigated using aliphatic polyester based nanoparticles and soluble polymer-
drug conjugates as well as micelles (Mo and Lim 2005; Olivier 2005; Nobs et al. 2006; 
Mundargi et al. 2008; Gaucher et al. 2010).  
Degradation of biodegradable polymers (i.e. through polymer chain cleavage) can take 
place in the body by passive or active hydrolysis (Göpferich 1997). Passive hydrolysis is 
attributable to water whereas active hydrolysis involves the action of enzymes. The 
following step is erosion which is defined the weight loss caused by the release of 
fragments from polymer matrix. Erosion can be divided into bulk (homogenous) or surface 
erosion (heterogenous). In bulk erosion, the polymer degrades evenly throughout matrix 
whereas a surface erodible material degrades on the surface only with a polymer having 
virtually unchanged molecular weight inside the matrix (Göpferich 1996; Göpferich 1997). 
The erosion mechanism of aliphatic polyesters is usually bulk degradation which can 
lead to a three phase release pattern of drug from the matrix (Sturesson and Wikingsson 
2000; Jain et al. 2000; Tarvainen et al. 2002a,b). An initial fast release phase is often caused 
by drug release at or near to the surface of device. Subsequently, the drug release is affected 
by diffusion through the polymer matrix and the rate of degradation and erosion. Finally, 
drug depletion in the matrix causes a slower release rate. Usually drug release follows 
square root of time pattern after the initial burst release phase. Surface erodible materials 
have attracted great interest because they can deliver drug molecules at a constant rate 
(Göpferich and Tessmar 2002; Katti et al. 2002; Heller and Barr 2004; Heller 2005). They 
have been under extensive research since they may help to develop aliphatic polyesters 
such that they would enable constant drug release via surface erosion. 
A biodegradable polymeric material must not only fulfill the required criteria for drug 
delivery and degradation rate and mechanism but also it must have appropriate 
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biocompatibility properties. Generally, the degradation of a biodegradable polymer is likely 
to produce a variety of degradation products. Therefore, the biocompatibility of new 
biodegradable polymers must be carefully evaluated; this is a legal requirement (Directive 
2007/47/EC).  
The aim of this study was to develop novel biodegradable polymers for pharmaceutical 
applications. Specifically, the suitability of novel 2,2-bis(2-oxazoline) linked poly(ε-
caprolactone) (PCL-O) and pegylated polylactic acid with biotin (biotin-PEG-PLA) was 
evaluated for controlled and targeted pharmaceutical applications. The focus of this study 
was on degradation mechanisms and safety evaluation in the case of PCL-O. Biotin-PEG-
PLA was prepared in the form of nanoparticles with an anticancer drug, paclitaxel, and the 
evaluation of avidin-biotin based cancer targeting was performed in vitro. 
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2 Review of the literature  
2.1 BIODEGRADABLE DRUG DELIVERY SYSTEMS 
Although the conventional oral administration of drugs is one of the simplest and safest 
ways for drug delivery, an oral formulation may confront many problems. For instance, 
many drugs, such as peptides and proteins, cannot be administered orally due to their 
negligible absorption and/or extensive degradation. An oral formulation may fail because 
of the frequently changing environments of gastrointestinal tract (i.e. variation in residence 
time and pH). Drug delivery systems based on biodegradable polymers can offer numerous 
advantages compared to conventional oral dosage forms:  1. Continuous maintenance of 
drug levels in a desirable range, 2. Reduction of harmful side-effects due to targeted drug 
delivery, 3. Lower amount of needed drug, 4. Decreased number of dosages and less 
invasive dosing leading to better patient compliance and 5. Possibility of delivery of drugs 
with short in vivo half-lives (Langer 1998). 
Controlled release formulation can be defined as a system which is able to deliver drugs 
in a controlled manner at predefined rates (Orloff et al. 1997; Wischke et al. 2010). 
Depending on the application, this can be sustained, fast or pulsatile delivery of drugs. For 
example, sustained delivery is highly beneficial for rapidly metabolized and eliminated 
drugs, such as peptides and proteins which have to be usually administered by daily 
injections because of their fast degradation in the body. The drug concentration can be held 
in a therapeutic window and the drug effect can be sustained without the side-effects 
associated with high concentrations. Furthermore, a drug delivery system can be targeted 
to an exact site of action (Brannon-Peppas and Blanchette 2004). This targeted delivery is 
beneficial with drugs possessing harmful side-effects and/or sites of therapeutic actions 
which are hard to reach with conventional drug delivery. 
Most of the synthetic biodegradable polymers have been originally developed for 
applications other than drug delivery. They have been utilized in various biomedical 
applications including suture materials, tissue adhesives, wound covers, dental 
membranes, bonds, clips, staples, screws, films, artificial ligaments, bone fracture fixatives, 
stents, meshes and more recently tissue engineering and bone regeneration scaffolds (Ueda 
and Tabata 2003; Vauthier et al. 2003; Kroeze et al. 2009). After their successful use in the 
biomedical field, biodegradable polymers have been subsequently utilized in controlled 
and targeted drug delivery. Biodegradable devices can be formed into solid or injectable 
implants in the form of rods, plugs, pellets, discs, gels, pastes, films, micro- and 
nanoparticles, micelles as well as polymer-drug conjugates such that their degradation and 
drug release can be modulated at a desired rate (Perrin and English 1997a,b; Jain 2000; 
Wischke and Schwendeman 2008; Mundargi et al. 2008). While nanoparticulate carriers of 
biodegradable polymers have been extensively studied in animal and clinical studies 
(Vauthier et al 2003; Olivier 2005; Owens and Peppas 2006; Gaumet et al. 2008; Gaucher et 
al. 2010), at present there are no polymer based nanoparticulate products on the market. 
The most common biodegradable polymers in the pharmaceutical field include aliphatic 
polyesters, such as poly(lactic acid) PLA, poly(glycolid acid) PGA, poly(ε-caprolactone) 
PCL (Perrin and English 1997a,b; Brannon-Peppas and Vert 2000; Wischke and 
Schwendeman 2008), poly(alkylcyanoacrylates) (Vauthier et al 2003), polyorthoesters (Barr 
et al. 2002; Heller et al. 2002; Heller and Barr 2004; Heller 2005) and polyanhydrides 
(Göpferich and Tessmar 2002; Katti et al. 2002). Aliphatic polyesters belong to one of the 
most widely studied groups of biodegradable synthetic polymers and they have achieved 
the greatest success in the market being used as implants and microparticulates due to 
biodegradability, safety and easy processing.  
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2.1.1 Polymer degradation and erosion 
Medical biodegradable polymers are interesting materials as they can degrade into smaller 
non-toxic units (monomers and oligomers), resulting in their disappearance from the body 
in urine, faeces or respiration (CO2), i.e. thereby avoiding the need for surgical removal. The 
term “degradation” is often utilized to describe as the cleavage of polymer chains, thus 
leading to smaller polymer chains (Göpferich 1997). Polymer degradation can proceed by 
four major mechanisms: 1) photo-, 2) mechanical-, 3) thermal- and 4) chemical degradation 
(Göpferich 1997). Chemical degradation is the most important mechanism of degradation of 
biodegradable polymers as the hydrolysable functional groups are introduced in the 
polymer backbone. Hydrolytic degradation can occur passively due to water hydrolysis or 
actively by enzymatic catalysis. Usually, synthetic polymers are degraded by passive 
hydrolysis because they do not contain enzyme specific susceptible structures. It must be 
noted that in many cases, enzymatically degradable polymers are subject to passive and 
active degradation i.e. both mechanisms are operating simultaneously.  
Erosion is defined as a process where a polymer loses weight due to the release of 
monomers, oligomers or pieces of the polymer matrix (Tamada and Langer 1993; Göpferich 
1997; Siepmann and Göpferich 2001). Erosion of the polymer can proceed either 
homogenously through the polymer matrix (bulk erosion) or heterogeneously on surface of 
polymer (surface erosion) (Tamada and Langer 1993; Göpferich 1997). These erosion 
mechanisms are illustrated in Figure 2.1. The polymer erosion mechanism is determined by 
rates of water penetration into the polymer matrix and the cleavage of polymer chains. Bulk 
eroding polymers degrade and erode throughout the matrix as water diffusion into the 
matrix is faster than the cleavage of the polymer chains (Figure 2.1:A). Surface eroding 
polymers degrade and lose material from the surface only due to a faster cleavage of 
polymer chains than water diffusion into the matrix (Figure 2.1:C). However, enzymatically 
surface eroding polymers are different in this respect as the water diffusion inside the 
matrix can be fast but the enzymes are unable to penetrate inside the polymer matrix, 
resulting in surface erosion. It must be noted that degradation products of a polymer may 
accelerate the degradation of the parent polymer and this can enhance the degradation rate 
inside the matrix. These materials are termed as bulk eroding polymers displaying 
autocatalytically accelerated degradation (Figure 2.1:B).  
 
 
Figure 2.1. Erosion mechanisms: (A) bulk erosion, (B) Bulk erosion with autocatalytically 
accelerated degradation and (C) surface erosion. 
A B C
Time 
 
Degradation    
degree 
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2.1.2 Degradation products  
Generally, the degradation of a biodegradable polymer produces a complex mixture of 
degradation products. These releasing degradation products may influence the toxicity of 
the biodegradable material (Cordewener et al. 2000). Therefore it is of great importance to 
identify the formed degradation products since this can also provide more specific 
knowledge of the polymer structure as well as the degradation mechanism. 
Hydrolytic and enzymatic degradation products of biodegradable polymers, including 
polyesters, have typically been studied by ultraviolet (UV) (Tsitlanadze et al. 2004a), high 
pressure liquid chromatography (HPLC/UV) (Kanesawa et al. 1994; Deschamps et al. 2004, 
Hakkarainen et al. 2008), capillary zone electrophoresis (CZE/UV) (Li et al. 2004; Vidil et al. 
1995), nuclear magnetic resonance (NMR) (Abe et al. 1994; Baran and Penczek 1995; Li et al. 
2002), X-ray (Baran and Penczek 1995) and Fourier transform infrared (FTIR) (Tsitlanadze 
et al. 2004a). The disadvantages of these methods include the lack of specificity and 
identification efficiency. Furthermore, some of the methods need standards for the studied 
substances as well as extensive purification of the samples. 
Methods based on mass spectrometry have become indispensable tools in polymer 
research since this technique complements the structural information gathered in 
conventional methods such as NMR (Montaudo and Montaudo 2002). In particular, 
powerful mass spectrometric methods have opened new areas in the analysis of the 
degradation products of polyesters (Table 2.1). Currently, atmospheric pressure chemical 
ionization mass spectrometry (APCI-MS) and electrospray ionization mass spectrometry 
(ESI-MS) with direct injection (Scandola et al. 1997; Focarete et al. 1999), and gas 
chromatography mass spectrometry (GC-MS) have been widely employed in 
characterization of degradation products of aliphatic polyesters (Witt et al. 2001). 
Furthermore, the MSn fragmentation techniques can be utilized to achieve a more specific 
identification, thereby revealing the chemical nature of a polymer and its end groups 
(Jedliński et al. 1998). As such, these methods usually need extensive purification of 
polydispersed biological samples, because direct injection of the sample into the mass 
spectrometer is difficult if the sample contains many different oligomers or other 
interfering compounds. Many of above mentioned mass spectrometric methods are suitable 
for analyzing only certain type of compounds.   
MS connected with on line separation HPLC is a rather new method for studying the 
soluble degradation products of aliphatic polyesters. HPLC connected to fast atom 
bombardment mass spectrometry (HPLC-FAB-MS) and electrospray ionization mass 
spectrometry (HPLC-ESI-MS) have been shown to be highly effective tools for the analysis 
of the enzymatic degradation products of polyesters (Ando et al. 1998; Rizzarelli et al. 2004; 
van Leeuwen et al. 2007). These methods enable direct analysis of soluble degradation 
products without any cumbersome purification process. In addition, problems associated 
with broad molecular weight distribution, such as cationization efficiency as a function of 
molecular weight, are greatly reduced (Prokai 2002). Furthermore, the ESI ion source is a 
gentle method for detecting molecules and therefore it is well suited for analyzing 
molecules with a wide range of chemical properties.  
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Table 2.1. Examples of mass spectrometrical methods suitable for characterization of 
degradation product of polyesters. 
  
Method Polymer Degradation medium Reference 
APCI-MS  PHB and PHBV hydrolytic, depolymerase A  Scandola et al. 1997 
   HPLC-APCI-MS mPEG-PCL-LA - van Leeuwen et al. 2007 
   HPLC-APCI-MS PBT hydrolytic Deschamps et al. 2004 
 
GC-MS PLLA, PCL hydrolytic, microorganisms  Hakkarainen et al. 2000, 
Hakkarainen and 
Albertsson 2002 
 Copolyester (Ecoflex) hydrolytic, microorganism Witt et al. 2001 
 
ESI-MS PCL-DXO hydrolytic Hakkarainen et al. 2008  
 PHLA hydrolytic Trimaille et al. 2007 
 PLA solvolytic (methanol) Osaka et al. 2006 
 PGA-PCL hydrolytic  Li et al. 2005 
 PHA,PHB,PHV hydrolytic, hydrolase, 
carboxyesterase 
Hardrick et al. 2001 
 PHB and PHBV hydrolytic, depolymerase A Scandola et al. 1997 
   HPLC-ESI-MS mPEG-PCL-LA - van Leeuwen et al. 2007 
 
ESI-MS/MS PCL/δ-
valerolactone/L-
lactide 
hydrolytic Faÿ et al. 2006 
 PCL-DXO hydrolytic Höglund et al. 2008 
 PHB hydrolytic, depolymerases  Focarete et al. 1999 
   HPLC-ESI-MS/MS P(BS-co-BSe),  
P(BS-co-BA) 
hydrolytic, lipase Rizzarelli et al. 2004 
MALDI PLA solvolytic (methanol) Osaka et al. 2006 
    
Methods: APCI: atmospheric pressure chemical ionization; GC: gas chromatography; ESI: electrospray 
ionization; MS: mass spectrometry; MS/MS: tandem mass spectrometry; MALDI: matrix-assisted laser 
desorption ionization mass spectrometry 
Polymers: BS: butylene succinate; BSe: butylene sebacate; BA: butylenes adipate;  DXO: 1,5-dioxepan-
2-one; LA: linoleic acid; mPEG: methyl(polyethylene-oxide); PBT: poly(butylene terephthalate); PCL: 
poly(ε-kaprolactone); PGA: poly(glycolic acid); PHA: poly((R)-3-hydroxyalkanoates); PHB: 3-
hydroxybutyrate;  PHBV: 3-hydroxybutyrate with 3-hydroxyvalerate;  PHV: poly(3-hydroxyvalerate); 
PHLA: poly(hexyl-substituted lactides); PLA: poly(lactic acid); PLLA: poly(L-lactic acid) 
 
 
2.1.3 Drug release  
The drug can be incorporated in polymeric devices in many different ways. The drug can 
be evenly distributed (dissolved or dispersed) in the polymeric matrix, covered with a 
polymer membrane (reservoir), covalently attached to polymer chains or even adsorbed 
onto the polymeric device. Drug release from biodegradable polymer devices is influenced 
by the physicochemical properties of both the drug (e.g. molecular weight, hydrophobicity) 
and the device (e.g. material, size, shape). A biodegradable polymeric device can release the 
drug by diffusion, chemical reaction (i.e. polymer degradation/erosion) or solvent 
activation (i.e. swelling or osmotic effect) mechanism (Langer 1990); it is the fastest of these 
processes that will control the drug release. Thus, in the case of diffusion controlled drug 
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release, drug diffusion out from the matrix is faster than degradation/erosion of the 
polymer. Instead, in the case of erosion-controlled release, only polymer matrix 
degradation and erosion allow drug release as erosion of the device is much faster than the 
diffusion of the drug molecule. Typically the drug release from a delivery system is not 
exclusively controlled by a single mechanism.  
 In the case of diffusion controlled drug release from the biodegradable polymer matrix 
(Figure 2.2:A), the drug is assumed to dissolve in the polymer matrix and to diffuse out 
from the surface of the matrix. Due to increasing distance for diffusion as a function of time, 
the drug release typically follows square root of time –kinetics (Figure 2.2:A). Matrix type 
devices typically contain channels and pores which can enhance the drug release as the 
drug can leach out through these pores.  
Drug release phenomenon becomes more complicated when it is erosion of polymer 
which is controlling the drug release from a bulk erodible device. The water diffusion into a 
bulk erodible polymer is faster than the degradation rate of polymer and only the 
substantial polymer matrix degradation and erosion allow drug release. Since bulk eroding 
polymers degrade over their entire cross-section area and have erosion kinetics that are 
non-linear (Göpferich and Tessmar 2002), the drug release profiles from these polymers are 
also non-linear and display discontinuity (Figure 2.2:B). 
 
 
 
 
Figure 2.2. Drug release mechanisms from biodegradable matrix devices can be divided into A) 
diffusion controlled, B) bulk erosion controlled and C) surface erosion controlled release. Drug 
release (constant line) and polymer degradation/erosion (dotted line) as a function of time in 
each case are shown on the right. 
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If the drug release from the surface erodible device is controlled by erosion, the 
degradation rate of the polymer is faster than the diffusion rate of water into the polymer. 
As a result, the degradation and erosion are limited only to the surface of polymer 
(Göpferich and Tessmar 2002). Since the polymer erosion and the resulting drug release 
kinetics are identical, the drug release should follow zero order kinetics (Figure 2.2:C) with 
the drug release being proportional to the surface area of the device (Katti et al. 2002).  
It should be noted that the drug release from a biodegradable device is typically 
controlled by several mechanisms. For example, macromolecule (FITC-dextran Mw 4400) 
release from PCL-O microparticles exhibited four phases: 1. burst phase (diffusion from the 
surface), 2. diffusional release phase (diffusion from near to the surface), 3. slower release 
phase (diffusion from the inner part), 4. final fast release phase (due to erosion of the 
polymer) (Tarvainen et al. 2002b).  
 
2.1.4 Biocompatibility  
In the case of biodegradable polymers, both polymer and its degradation products must be 
nontoxic. Therefore it is of major importance to study the biocompatibility properties of 
new polymers. Immediately after soft tissue implantation, the implant site displays signs of 
acute trauma which is followed by fibrous capsule formation around the implant (Perrin 
and English 1997a). This inflammation is intended to protect the body from tissue damage 
by isolating and destroying any foreign material (Bauman and Gauldie 1994).   It should be 
noted that creation of a fibrous capsule is a normal reaction against implanted material and 
it is not an adverse effect due to non-biocompatibility (Tang and Eaton 1995). However, 
from the drug delivery point of view, the fibrous capsule can be problematic as it may 
reduce the drug release rate from the implanted device. 
Many factors can affect the host response to an implanted material, including species, 
genetic inheritance and site of implantation (Andersson and Shive 1997; Fournier et al. 
2003). In addition, material properties, such as shape, size, surface chemistry, porosity, 
composition, sterility and contact time as well as degradation rate are crucial in 
determining the extent of the inflammatory response (Mikos et al. 1998; Rihova 2000; 
Fournier et al. 2003). The tissue reaction against a biodegradable device can be divided into 
three different phases (Andersson and Shive 1997; Fournier et al. 2003). The first phase 
occurs during the first two weeks after implantation and involves acute inflammation and 
the initiation of chronic inflammatory responses. This inflammation reaction is started by 
mechanical injury due to the implantation procedure and the material itself. Immediately 
after implantation, the non-specific adsorption of blood and tissue fluid proteins occurs on 
the device (Williams 1987). A protein layer is formed over a few hours which consists of 
many proteins (e.g. immunoglobulins, complement components, antithrombin III, 
transferrin, fibronectin, laminin, albumin, growth factors) (Tang and Eaton 1995; Rihova 
2000; Ratner 2002). These proteins are likely to undergo conformational changes due to 
adsorption which in turn leads to recruitment of inflammatory cells to the vicinity of the 
implant (Tang and Eaton 1995). Initially, large numbers of neutrophils gather around the 
implantation site, but also monocytes and lymphocytes may be attracted to the area 
(Williams 1987; Andersson and Shive 1997; Ratner 2002). Thereafter, macrophages are 
transferred close to the implanted material. As blood vessels dilate, the cells can effectively 
move into the implantation area. In this acute phase, monocytes, macrophages, fibroblasts 
and endothelial cells will produce cytokines (e.g. interleukin-1, interleukin-6, and tumor 
necrosis factor-α) which are chemical agents which mediate this phase (Rihova 1996).  
The second phase is initiated by a predominance of monocytes and macrophages, but 
also an increase in the numbers of fibroblast and lymphocytes is often encountered. The 
length of this phase is dependent on the degradation rate of the device. Macrophages may 
fuse together and form foreign body giant cells which are thought to be prominent in more 
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efficient reactions (Ratner 2002). At the implant site, fibroblasts will start to produce the 
fibrous capsule. 
The third stage starts with a device breakdown. This initiates a tissue response where 
macrophages are the prevailing cell type. It has been postulated that polymer particles 
larger than 10 µm are not phagocytosed (by macrophages) until their size has been reduced 
due to degradation (Andersson and Shive 1997). It has been proposed that the degradation 
of phagocytosed aliphatic polyesters particles is rapid as macrophages and giant cells are 
able to produce acids and other agents which can enhance degradation (Tabada and Ikada 
1988 and 1990). Usually, the fibrous capsule will thicken during phase III as fibroblasts and 
new capillaries are filling the cavity formed due to the degradation of device at the site of 
implantation. The length of this phase is dependent on the degradation rate but it can last 
from weeks to several months. When the implant causes permanent inflammatory 
stimulus, a granuloma may occur (intense inflammation with the accumulation of 
macrophages and lymphocytes) with the presence of several foreign body giant cells, 
oedema and pain. If the material is highly toxic, macrophages die and the released 
compounds can evoke tissue damage, even to necrotic tissue death (Vert et al. 1994b; Tang 
and Eaton 1995).   
2.2 BIODEGRADABLE ALIPHATIC POLYESTERS IN DRUG DELIVERY 
SYSTEMS 
The aliphatic polyesters, such as PLA, PGA and PCL, are among the most extensively 
investigated and widely utilized synthetic polymers in biomedical and pharmaceutical 
applications, and several commercial products based on the aliphatic polyesters are 
available (Table 2.2).  Their success is based on extensive toxicological and clinical data 
which have confirmed their biocompatibility, biodegradability and functionality in drug 
delivery systems (Lewis 1990; Pitt 1990; Athanisiou et al. 1996; Perrin and English 1997a,b; 
Brannon-Peppas and Vert 2000; Mundargi et al. 2008; Wischke and Schwendeman 2008).  
Aliphatic polyesters can be synthesized using several routes such as step growth 
polymerization, postcondensation of macromonomers and ring opening polymerization 
(Brannon-Peppas and Vert 2000). High-molecular-weight polymers of aliphatic polyesters 
are very difficult to obtain by direct polymerization (i.e. condensation polymerization). 
Therefore, aliphatic polyesters and their copolymers are usually made by ring opening 
polymerization from cyclic diester dimers (Perring and English 1997a). This reaction 
requires an initiator such as stannous octoate or zinc lactate (Brannon-Peppas and Vert 
2000). The synthesis route and initiators should be carefully decided as they can affect the 
properties of the polymer product (Brannon-Peppas and Vert 2000). 
The development of aliphatic polyesters started from suture materials. During the 1970s, 
biodegradable suture material of PGA (Dexon®) was launched by D&D Co. (Herman et al. 
1970). Subsequently, Ethicon Inc. developed an improved multifilament suture of PGA-
PLA (90/10) which has been a great success on the market (Blomstedt and Jacobson 1977). 
The multifilament suture is superior in flexibility and handling, but its rough surface may 
cause problems due to the risk of infection and friction. Therefore, monofilament sutures 
such as Monocryl® made of PGA-PCL have been developed to avoid this problem 
(Bezwada et al. 1995). 
After their successful introduction as suture materials, the pharmaceutical applications 
of aliphatic polyesters have been extensively studied. The possibility of drug release 
adjustment lasting from days to years has been exploited in implants, rods, plates, tablets, 
capsules, beads, cylinders, fibers, films, pastes, granules, microparticles, nanoparticles and 
micelles (Perrin and English 1997b; Brannon-Peppas and Vert 2000; Jain 2000; Mundargi et 
al 2008; Wang et al. 2008b). During this journey, they have acquired a vast variety of 
marketed applications in the form of implants and microparticles for proteins, peptides and 
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smaller drug molecules (Table 2.2). Advances in drug delivery technology have led to 
increased development of combination products which have both medical and drug 
delivery characteristics at the implantation site. For example, drug eluting stents (Grube et 
al. 2004; Vogt et al. 2004; Guo et al. 2009) and screws (Tiainen et al. 2006) with 
antiproliferative or antibiotic agents have been successfully tested for the prevention of 
inflammation and restenosis. 
Various manufacturing methods are available for processing aliphatic polyesters for 
different applications. For example, drug containing films and discs can be prepared using 
solvent casting method, compression molding or melt pressing of polymer and drug (Pitt 
1990; Li et al. 1996; Song et al. 1996). The melt extrusion process has been used for the 
preparation of tubes and rods (Pitt 1990; Jain 2000). Lyophilization has been successfully 
applied in the development of foams (Hsu et al. 1996) and melt-spinning has been utilized 
for fiber production (Schmack et al. 2003). Since polymeric microparticles are commonly 
used, a wide range of manufacturing methods, such as emulsion solvent 
evaporation/extraction, phase separation, spray drying and supercritical fluid technologies,  
have been designed for different polymers and drugs (O’Donnell and McGinity 1997; Jain 
2000; Brannon-Peppas and Vert 2000; Yeo and Kirana 2005; Järvinen et al. 2008; Wischke 
and Schwendeman 2008).  
One patented in situ forming implant (Atrigel technology®) has achieved commercial 
status in a couple of products (Table 2.2). This system consists of polymer dissolved in a 
solvent such as N-methyl-2-pyrrolidone (NMP) with active drug being mixed into the 
polymer solution (Jain 2000; Matschke et al. 2002). After subcutaneous (s.c.) or 
intramuscular (i.m.) injection, the solvent is withdrawn from the system (due to 
surrounding water) and the implant solidifies, encapsulating drug in a controlled release 
system. This system is claimed to be cost effective because it does not require any 
demanding preparation procedure. However, it may not be suitable for drugs with small 
therapeutic windows as the size and shape of the implant may lead to a variation in the 
drug release rate (Winzenburg et al. 2004). Moreover, the NMP solvent can cause painful 
reactions during application (Matschke et al. 2002). 
During the past decades, nanotechnology has been considered as a promising way for 
developing controlled and targeted drug delivery devices. Polymeric nanoparticles can be 
prepared using the same methods as with microparticles, but the manufacturing 
parameters have to be adjusted to the submicron size (Jain 2000). While nanoparticles and 
self assembling micelles made of aliphatic polyesters have not yet achieved commercial 
status, remarkable research efforts have been exerted in this area (Olivier 2005; Byrne et al. 
2008; Xiong et al. 2008; Gaucher et al. 2010; Ruenraroengsak et al. 2010). In particular, tumor 
and brain targeting have achieved substantial attention as nanoparticulate formulations 
have been shown to be able to penetrate into the cancer and brain tissue (Kreuter 2001; 
Brannon-Peppas and Blanchette 2004; Olivier 2005). In fast growing tumors, the leaky 
vasculature and poor lymphatic drainage enables passive targeting of nanoparticles into the 
tumor due to enhanced permeation and retention effect (EPR) (Brannon-Peppas and 
Blanchette 2004). Passive targeting of nanoparticles into various cancer cells and tissues can 
be enhanced by inclusion of active targeting moieties such as vitamins, carbohydrates, 
aptamers, peptides, antibodies and their fragments (Byrne et al. 2008; Xiong et al. 2008; 
Rieger et al. 2009; Bondioli et al. 2010; Gaucher et al. 2010; Yu et al. 2010). Although 
intravenous (i.v.) administration offers opportunities in targeted drug delivery, it is 
complicated because of the rapid clearance of particles through the reticuloendothelial 
system (RES). This phagocytosis is facilitated by plasma protein adsorption on 
nanoparticles (i.e. opsonisation) resulting in their accumulation mainly in liver and spleen 
(Lherm et al. 1992; Kattan et al. 1992). Nanoparticle coating with hydrophilic substances 
such as polyethylene glycol (PEG) have been shown to protect nanoparticles from rapid 
uptake by RES and in this way one can extend their plasma half-lives (Bazile et al. 1995; Li 
et al. 2001).  
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Table 2.2. Examples of commercially available pharmaceutical products of PLA and PLGA. 
  
Drug (Mw) Product Polymer  Application  Duration 
of Action 
Company 
 
Microparticles  
buserelin     Suprecur MP PLGA endometriosis, i.m. 1 month Sanofi-Aventis 
(1239 g/mol) Suprefact 
Depot 
PLGA prostate cancer, children 
with central precocious 
puberty, i.m. 
3 months Sanofi-Aventis 
human growth 
hormone (hGH) 
(~22 000 g/mol) 
 
Nutropin 
depot 
PLGA treatment of growth 
failure, s.c. 
2-4 
weeks  
Genetech 
lanreotide   
(1096 g/mol) 
 
Somatuline 
PR 
PLGA acromegaly, i.m. 2-4 
weeks  
Ipsen 
leuprolide/ 
leuprorelin  
(1209 g/mol) 
Lupron 
Depot 
PLA,PLGA Prostate cancer, 
endometriosis, children 
with central precocious 
puberty, i.m.  
1, 3 and 
4 months  
TAP 
Pharmaceuticals 
 Procren 
depot 
 
PLGA prostate cancer, breast 
cancer, endometriosis, 
i.m.  
1 and 3 
months 
Abbott 
minocycline  
(457 g/mol) 
 
Arestin PLGA  periodontitis, local 
powder  
2-3 
weeks  
OraPharma 
naltrexone    
(341 g/mol) 
 
Vivitrol PLGA alcohol dependence 
treatment,  i.m. 
1 month Alkermes 
octreotide   
(1019 g/mol) 
 
Sandostatin 
LAR 
PLGA-
glucose 
acromegaly, i.m. 1 month Novartis 
triptorelin   
(1311 g/mol) 
Decapeptyl 
Depot 
PLGA Prostate cancer, 
endometriosis, i.m. 
1 month Ferring 
 Decapeptyl 
SR 
PLA,PLGA  1 and 3 
months 
Ipsen 
 
 
 
Trelstar 
LA/Depot 
PLGA  1 and 3 
months 
Pfizer 
risperidone   
(410 g/mol) 
 
Risperdal 
Consta 
PLGA  schizophrenia, i.m. 2 weeks Janssen-Cilag 
Implants       
buserelin    
(1239 g/mol)) 
Suprefact PLGA prostate cancer, children 
with central precocious 
puberty, s.c.  
3 months Sanofi-Aventis 
doxycycline  
(444 g/mol) 
Atridox PLA  
(in NMP 
solution) 
periodontitis, in situ 
forming implant 
7 days Atrix 
Laboratories 
goserelin    
(1269 g/mol) 
Zoladex PLGA prostate cancer, breast 
cancer, endometriosis, 
i.m.  
1 and 3 
months 
AstraZeneca  
leuprolide    
(1209 g/mol) 
Eligard  
 
PLGA        
(in NMP 
solution)  
Prostate cancer, 
endometriosis, in situ 
forming implant.  
1,3,4 and 
6 months 
Sanofi-Aventis 
NMP: (N-methyl-2-pyrrolidone); PLA: poly(lactic acid); PLGA: poly(lactide-co-glykolide);  
s.c.: subcutaneous; i.m.: intramuscular 
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2.2.1 Degradation of poly(α-hydroxyesters): PLA, PGA and PLGA 
PLA is a linear polymer consisting of repeated lactic acid monomers (Figure 2.3). It has a 
chiral methyl group at the alpha carbon which leads to the existence of L, D and DL 
isomers. L-PLA (PLLA) form is crystalline (~35%) showing glass transition and melting 
temperature of ~65°C and ~175°C, respectively. The racemic mixture of L and D (PDLLA) is 
completely amorphous with a glass transition temperature around 57°C. PLAs are soluble 
in common organic solvents such as chloroform and dichloromethane (Perrin and English 
1997a). 
PLLA degrades much slower than PDLLA due to differences in its crystallinity (Perrin 
and English 1997a). It is well-known that the amorphous parts degrade faster than the 
crystalline parts and, thus in the semicrystalline polymers, degradation occurs in the 
amorphous regions during an earlier stage of degradation, leaving the crystalline areas 
more intact. As this process continues, increased crystallinity results in a more resistant 
structure against hydrolysis (Bostman et al. 1990; Bergsma et al. 1993).  
 
 
O
CH3
O
n
 
O
H
O
n
 
     PLA                                       PGA  
 
Figure 2.3. Structures of polylactic acid (PLA) and polyglycolic acid (PGA)      
 
 
Copolymers of PLA have been explored with various polymers (e.g. lactones, lactides, 
cyclic carbonates, glycolides, lactams) to improve the physical and mechanical properties as 
well as degradation rate of PLA (Perrin and English 1997a, Ueda and Tabata 2003). Usually, 
degradation of copolymers is faster than that of homopolymers due to the reduced 
crystallinity of the copolymers (Pitt et al. 1981b; Perrin and English 1997a). PLA is 
frequently co-polymerized with poly(glycolic acid) (PGA), resulting in polymer called 
poly(lactic-co-glycolic acid) (PLGA). PGA is a highly crystalline polymer, having a 
crystallinity between 35-75%, a melting point ~225ºC and a glass transition temperature ~35 
ºC (Lewis 1990).  When compared to PLA, PGA degrades faster due to the absence of the 
methyl group (Figure 2.3) (Vert et al. 1994a,b; Perrin and English 1997a; Alexis 2005). The 
solubility of PGA is poorer in common organic solvents when compared to PLA 
(Andersson and Shive 1997).  
It is generally accepted that aliphatic polyesters undergo bulk degradation and they are 
degraded by passive hydrolysis (Andersson and Shive 1997). There are a few reports 
suggesting that enzymes may take part in the degradation of PLA based polymers 
(Schakenraad et al. 1990) but this enzymatic degradation seems to be insignificant as the in 
vitro (buffer solutions in the absence of enzymes) and in vivo degradation profiles of PLA 
have been reported to be similar (Perrin and English 1997a). In the case of PGA, 
extracellular enzymes are thought to influence degradation and thus the extracellular 
degradation of PGA occurs by a combination of passive and active hydrolysis in vivo.  
Degradation of aliphatic polyester based biodegradable devices in vivo takes place in the 
following steps (Perrin and English 1997a). First, the hydration of the specimen occurs 
when the device is placed in the body. The time needed for water absorption can last from 
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hours to months. Then, the degradation of polymer chains starts and the mechanical 
properties of specimen decline depending on the polymer properties. It is belived that the 
amorphous parts are more susceptible to degradation and that they will degrade first. 
During this step, the mass of the device remains unchanged. The third stage involves the 
fragmentation of the implant as its cohesive properties become reduced. At this stage, the 
size of the implant starts to decrease. The fourth stage is absorption which takes place 
because the fragment size is appropriate for phagosytes or hydrolysis and this leads to the 
appearance of soluble monomeric chains which dissolve in the intercellular liquid. During 
this stage, there is a clear loss of mass. The final stage is the elimination of the polymer. L-
lactate is converted into carbon dioxide and pyruvate which is taken into the Krebs cycle 
through the acetylation of Coenzyme A. The majority of PLA degradation products are 
eliminated via respiration as CO2 and only a minor part are excreted via urine and/or 
faeces. PGA hydrolysis results in the formation of glycolate which is excreted through urine 
though some glycolate can be oxidized to glyoxylate which will be converted to glycine, 
serine and pyruvate. Pyruvate is handled in the Krebs cycle similarly as lactate. It has been 
reported that biodegradation of the fastest (PLGA (50/50)) and the slowest (PLLA) 
degrading poly(α-hydroxyesters) ranges from approximately from 2 months up to 2 years, 
respectively (Lewis 1990). However, it should be borne in mind that the biodegradation of 
small molecular weight polymers can occur much faster.  
Various factors have been claimed to take part in the degradation process of aliphatic 
polyesters (Table 2.3). The molecular weight and molecular weight distribution of the 
polymer can play a role in the degradation process. A wide molecular weight distribution 
would likely enhance the autocatalytic degradation since there should be a large number of 
carboxylic end groups (Andersson and Shive 1997). Kamei et al. (1992) studied in vivo 
degradation of PLGA (75:25) microspheres (53-75 µm) made of 10 000 and 20 000 Mw 
polymers. They found that the 10 000 Mw polymer was degraded approximately two times 
faster after subcutaneous or intravenous application in rats when compared to the 20 000 
Mw polymer.  
 
 
  Table 2.3. Examples of factors affecting the degradation rate of aliphatic polyesters. 
 
Main factor Examples of specific factors 
 
Chemical composition  
 
 
molecular weight and molecular weight distribution  
type of monomers 
distribution of co-units/chiral units 
ionic groups  
hydrophilicity/hydrophobicity 
crystallinity 
 
Device dimensions  
 
size 
shape 
surface to volume ratio  
porosity 
 
Additives and storage 
 
monomers, oligomers 
solvents 
drugs 
initiators 
acid or basic substance  
aging conditions (pH, temperature, enzymes) 
 
Processing  
 
sterilization 
heat 
force 
 
   (Table has been modified from Andersson and Shive 1997; Brannon-Peppas and Vert 2000) 
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The size of the device affects strongly the degradation rate of PLA and PLGA based 
polymers. Grizzi et al. (1995) studied the in vitro degradation profiles of plates 
(15x10x2mm) and submillimetric films and particles of PDLLA. They found that the larger 
PDLLA devices were degraded heterogeneously (faster inside than on the surface) and the 
degradation was faster than the degradation of films and particles that were degraded 
homogenously. These results can be explained by the fact that during the degradation 
process, each ester bond cleavage produces a new carboxyl (-COOH) end group which can 
catalyze the degradation of the remaining groups (Pitt et al. 1981b). In the large devices,  
the degradation products deep inside the device are not able to diffuse out which creates an 
autocatalytic situation inside the device and thus, the degradation proceeds faster inside 
than outside the device (Brannon-Peppas and Vert 2000; Alexis 2005). The heterogenous 
degradation of large size PDLLA devices has been confirmed in vitro as well as in vivo (Vert 
et al. 1994a,b; Grizzi et al. 1995). Instead, PDLLA microspheres smaller than 300 µm 
underwent homogenous degradation in vitro and in vivo (Spenlehauer et al. 1989). In 
addition to size, porosity of PLA and PLGA based delivery system may decrease the 
degradation rate of the polymer which can be explained by the better diffusion of 
degradation products out from the device (Pistner et al. 1993). However, in vivo, this 
situation can become more complicated as the porosity may increase cellular migration into 
the pores (Anderson and Shive 1997).  
Incorporated basic and acidic substances can affect the degradation characteristics of 
aliphatic polyesters. With acidic drugs, one could expect a more rapid degradation whereas 
basic drugs have been reported to show a dual effect on degradation (Brannon-Peppas and 
Vert 2000).  Basic drugs can decrease the degradation rate of the polymer as an appropriate 
amount of basic substances are able to neutralize the acidic groups of the polymer, resulting 
in a slower degradation of the polymer (Mauduit et al. 1993; Andersson and Shive 1997). 
On the other hand, the degradation rate of PDLLA increased when the basic, nucleophilic 
nitrogen containing compound thioridazine, was incorporated into the polymer (Maulding 
et al. 1986). 
It should be remembered that harsh preparation methods of drug delivery systems can 
enhance the degradation of the polymer. Injection molding reduced the molecular weight 
of PLA (Alexis 2005), sterilization affected chemical composition of PLGA (Faisant et al. 
2002) and high temperature during the melt-extrusion of PLA (D form) resulted in 40% 
reduction in the molecular weight of the polymer (Weller and Godolewski 1996). Further, 
the preparation of PDLLA microparticles by solvent evaporation method reduced its 
molecular weight (Park 1994).  
2.2.2 Degradation of poly-ε-caprolactone (PCL)  
Poly-ε-caprolactone (PCL) (Figure 2.4) is a hydrophobic and semicrystalline polymer 
showing a glass transition temperature (Tg) ~ -60°C and a melting point (Tm) ~60°C (Perrin 
and English 1997b). PCL has good solubility in many organic solvents such as chloroform, 
tetrahydrofuran, methylene chloride and benzene. 
 
O
O
n
 
      PCL  
 
Figure 2.4. Structure of poly-ε-caprolactone (PCL) 
15 
 
 
 
PCL has been used in various pharmaceutical and biomedical applications, including 
suture coatings, medical devices, intravascular stents, vein grafts, tissue engineering 
scaffolds, casting material for broken bones and dental impression trays (Perrin and English 
1997b; Woodroff and Hutmacher 2010). PCL, along with PLA based polymers, is the most 
widely studied of the aliphatic polyesters for use in controlled drug delivery systems. The 
advantages of PCL include its high permeability for low molecular weight drugs (< 400 Da) 
(Pitt 1990), its good suitability for incorporation with various other polymers i.e. polymer 
blends or copolymers (Perrin and English 1997b) and the lack of creation of an acidic 
environment during its degradation. Due to the high permeability of PCL, the release of 
small molecules from PCL based films and microparticles is typically rapid, exhibiting 
square root of time kinetics (Hombreiro Pérez et al. 2000; Tarvainen et al. 2002b; Perrin and 
English 1997b). Reservoir devices of PCL have been developed to achieve a constant drug 
release. However, constant release may be difficult to achieve if the dissolution of a drug in 
the polymer wall is the rate limiting step. For example, testosterone release from the 
thinnest wall capsules (0.60 mm) was reduced by one-fourth over 80 days, whereas 
testosterone release from the thickest wall capsules (2.25 mm) followed zero-order kinetics 
during this time but the actual release rate was lower from the thickest wall capsules (Pitt et 
al. 1979). Since PCL does not generate an acidic pH during its degradation, it has been 
evaluated for use in the delivery of macromolecules, such as peptides and proteins, which 
may be degraded at low pH values (Baras et al. 1999; Benoit et al. 1999; Jiang and 
Schwendeman 2001). However, an unmodified PCL may not be suitable for the 
macromolecule delivery due to the slow diffusion of the macromolecules from the polymer 
and the slow bulk degradation of PCL (Holland et al. 1986).  
The biodegradation of a high molecular weight PCL homopolymer may take from two to 
four years (Middleton and Tipton 2000, Gunatillake and Adhikari 2003).  It has been 
proposed that the first step in PCL biodegradation takes place by passive hydrolysis due to 
random hydrolytic chain scission (Woodward et al. 1985; Pitt 1990). Autocatalysis by the 
formed carboxylic end groups is possible, but this seems to be insignificant as the 
degradation rate of PCL was not affected by the size of the device (Pitt 1990). The second 
step is characterized by a decrease in the chain degradation rate and the start of weight loss. 
This starts when the molecular weight of the polymer is around 5000 g/mol (Mn) as this is 
the limiting size when the short chain oligomers are able to escape from the matrix (Pitt 
1990). Then the matrix is able to break down to smaller phagocytable particles. During this 
step, the crystallinity of the polymer increases which is a result from more susceptible 
degradation of the amorphous parts and the crystallization of the remaining segments (Pitt 
1990). When the size of polymer particle is suitable for phagocytosis by macrophages, giant 
cells or fibroblasts, the degradation of the polymer continues rapidly. Metabolism of PCL 
has been studied using radioactive labeled low molecular weight PCL (Pitt 1990). ε-
Hydroxycaproic acid was the only metabolite with water which could be detected in urine, 
faeces, expired air and at the implant site. The hydroxyl free radical has been reported as 
being mostly responsible for the degradation of PCL in vivo (Ali et al. 1993). Enzymes do 
not appear to exert any significant effect on the degradation of PCL as the degradation rate 
of the polymer is similar in vitro and in vivo (Pitt 1990). However, three bacterial lipases 
(Fukuzaki et al. 1990; Mochizuki et al 1995; Gan et al. 1997) as well as bacteria, yeast and 
fungi  (Benedict 1983a,b; Eldsäter et al. 2000; Ponsart et al. 2001) have been shown to 
enhance the degradation of PCL.   
The slow degradation rate of PCL is not appropriate for many applications, therefore the 
structural tailoring of PCL by copolymerization and polymer blending has been widely 
examined. Usually, the degradation rate of PCL can be increased by copolymerization and 
blending with other biodegradable polymers, most probably due to the reduced amount of 
crystallinity of the polymer which increases the hydrolysis of the ester bonds (Perrin and 
English 1997b).  Copolymers of PCL have been made with polyethylene glycol, polystyrene, 
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urethanes, polyvinylchloride, methyl methacrylate, lactide, glycolide, γ-valerolactone and 
ε-decalactone (Perrin and English 1997b, Pitt 1990). The degradation rate of a random 
copolymer of dilactide and ε-caprolactone is more rapid than that of either homopolymer 
whereas the degradation rate of a block copolymer of the same constituents is intermediate 
from the homopolymers (Feng et al. 1983). Similarly, a blend of PLGA and PCL degrades at 
an intermediate speed when compared to the original pure polymers (Cha and Pitt 1990). In 
addition, in the Monocryl® suture, PGA causes a more rapid degradation of PCL as PGA-
PCL suture retained only 50 % of its original strength after a mere week whereas the plain 
PCL suture still retained half of its original strength after one year implantation (Perrin and 
English 1997b). 
Interestingly, copolymerization of PCL may also result in enzyme sensitive polymers. 
The enzyme sensitivity of PCL copolymer has been reported for copolymers with ε-
decalactone (Pitt et al. 1990) and γ-valerolactone (Pitt et al. 1984, Pitt 1990). The in vitro 
degradation of copolymer of ε-caprolactone and γ-valerolactone (1:1) proceeded by 
hydrolytic chain cleavage, but in vivo the hydrolytic bulk degradation was accompanied by 
fast surface erosion which was complete within 12-16 weeks in the rabbit and 7 weeks in 
the rat. It has been postulated that the co-monomer mixture suppressed the crystallization 
of the polymer resulting in a faster degradation rate due to the higher sensitivity of the 
polymer to breakdown by enzymes.  
The work of Pitt (1990) with PCL culminated in the development of the Capronor® drug 
delivery system. This 1-year contraceptive device consists of a PCL capsule containing a 
levonorgestrel-ethyl oleate slurry inside the capsule which prolonged the dissolution of 
drug. Darney et al. (1992) reported that 2.5 cm subdermal Capronor® rod (containing 12 mg 
levonorgestrel) was not efficient enough to suppress ovulation in a Phase II clinical study. 
In the same study, 4.0 cm long rod (containing 21.6 mg levonorgestrel) suppressed 
ovulation in 80 % of the cycles over 1-year use, but a few pregnancies did occur. Earlier 
pharmacokinetic studies had revealed that in vivo release rate was only 65 % of the in vitro 
value, which was attributed to less effective sink condition in vivo (Henren et al. 1984). This 
slower drug release might have an accounted for the unwanted pregnancies and this factor 
will need to be taken into account when developing similar PCL based drug delivery 
systems.  
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3 Aims of the Study 
The general objective of the study was to study modified aliphatic polyesters for controlled 
and targeted drug delivery. The specific aims of the study were as follows: 
 
 
 
1. To evaluate the effect of the PCL block length on the in vitro degradation and weight 
loss of oxazoline modified poly(ε-caprolactone) (PCL-O) films in the presence or 
absence of enzymes and enzyme inhibitors.  
 
 
2. To develop sensitive and efficient MS method for analyzing in vitro degradation 
products of PCL-O films. 
 
 
3. To evaluate the effect of the PCL block length on the in vivo degradation and weight 
loss of PCL-O discs as well as the biocompatibility of the PCL-O discs. 
 
 
4. To develop paclitaxel-loaded stealth PLA-PEG nanoparticles which could be 
targeted into the brain cancer cells via three-step avidin–biotin technology and to 
investigate the functionality of the targeted nanoparticles in vitro.  
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4 General Experimental Procedures 
4.1 MATERIALS 
For polymer synthesis, ε-Caprolactone (6-hexanolactone) was purchased from Solvay 
Interox (Warrington, UK), and Sn(II)octoate (Sn(II)2-ethylhexanoate) from Sigma-Aldrich 
(St Louis, USA). 1,4-Butanediol and succinic anhydride (2,5-Furandione) were products of 
Acros Organics (Geel, Belgium). 2,2´-Bis(2-oxazoline) was supplied by Tokyo Kasei Organic 
Chemicals (Tokyo, Japan). For enzymatic degradation and erosion studies, pancreatin from 
porcine pancreas (P-1500), aprotinin, ethylene glycol bis(2-aminoethyl ether)-N,N,N'N'-
tetraacetic acid (EGTA), phenylmethanesulfonyl fluoride (PMSF), 4-(2-Aminoethyl)-
benzenesulphonyl fluoride (AEBSF), ε-amino-n-caproic acid (EACA), 1,10-phenanthroline, 
diethyl p-nitrophenyl phosphate (Paraoxon-ethyl) and tetrahydrolipstatin (THL) were 
provided by Sigma-Aldrich (St Louis, USA). GM6001 and ethylenediaminetetraacetic acid 
(EDTA-Na2) were provided by Merck Biosciences (Darmstadt, Germany). For HPLC 
analysis, acetonitrile (HPLC S grade) was obtained from Rathburn (Walkerburn, UK) and 
ammonium acetate from Riedel-de Haen (Seelze, Germany). For in vivo studies, 
medetomidine (Domitor®) and atipamezole (Antisedan®) were obtained from Orion 
Pharma (Espoo, Finland) and ketamine (Ketalar®) and carprofen (Rimadyl vet®) were 
products of Pfizer (Espoo, Finland). Water was purified and deionized in a Milli-Q system 
(Millipore). Other materials were of reagent grade. 
4.2 METHODS 
4.2.1 Polymerization of PCL-O polymers       
Oxazoline linked -caprolactone polymers (PCL-O) were polymerized in a three-step 
synthesis at the Helsinki University of Technology (nowadays Aalto University, School of 
Science) as described earlier (Tuominen et al. 1999). In the first step, hydroxyl-terminated 
prepolymers were prepared by ring-opening polymerization of -caprolactone in the 
presence of a co-initiator containing the hydroxyl group. In the second step, these 
prepolymers were further functionalized in a reaction of hydroxyl groups with succinic 
anhydride to obtain intermediates with carboxylic acid end groups. In the third step, 
carboxyl-terminated telechelic prepolymers were chain extended with 2,2’-bis(2-oxazoline) 
to produce poly(ester-amides) defined as PCL-O. The simplified synthesis steps are 
presented in Figure 4.1. 
The prepolymer syntheses (Helminen et al. 2003; Korhonen et al. 2004) as well as the 
chain extending procedure (Tuominen and Seppälä 2000) have been described elsewhere. 
In the present work, hydroxyl-terminated prepolymers were prepared by ring-opening 
polymerization of ε-caprolactone by using 0.03 mol % of Sn(II)octoate as an initiator and 
1,4-butanediol as a co-initiator. The molecular weights of the prepolymers were controlled 
by the ratio of 1,4-butanediol to -caprolactone monomer (1/100, 2/100, 5/100 and 10/100). 
The higher the amount of co-initiator used, the lower the molecular weight of the 
prepolymer.  The ring-opening polymerization reaction was carried out at 60 rpm and 
160°C for 6 h under a nitrogen atmosphere in a 2.5 dm3 DIT Helicone Mixer batch reactor 
(Design Integrated Technology, Inc., Warrenton, Virginia, USA). The hydroxyl-terminated 
prepolymer was converted to a carboxyl-terminated prepolymer by reacting it with a slight 
molar excess of succinic anhydride (at a molar ratio of end groups 1.05-1.5/1.0 (SAH/OH)) 
in a 2.5 dm3 DIT batch reactor at 60 rpm and 160°C for 1 h. Carboxyl-terminated 
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prepolymers were linked with 2,2´-bis(2-oxazoline) as a chain extender in a 150 cm3 DIT 
Helicone Mixer batch reactor in a nitrogen atmosphere at 60 rpm and 200°C for maximum 
of 3 h. The polymer synthesis was followed by 1H-NMR and size exclusion 
chromatography (SEC). Samples were taken as a function of the polymerization time, and 
1H-NMR was used to verify the completion of the different steps. Changes in molecular 
weights were determined by SEC during the chain-linking step. 
The polymerization of -caprolactone (PCL) was carried out in a 2.5 dm3 DIT batch 
reactor under a nitrogen atmosphere using 0.25 mol % of 1,4-butanediol as an initiator and 
0.01 mol% of Sn(II)octoate as a catalyst. After polymerization, PCL and PCL-O were 
purified twice by precipitation polymer/dichloromethane solutions (50 % w/v) with excess 
of ethanol, and dried for 24 h under reduced pressure at 40°C. 
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Figure 4.1 Synthesis of PCL-O polymers. 
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4.2.2 PCL-O polymers characterization  
Molecular weights (Mw, Mn) were determined by size exclusion chromatography (SEC) 
(Waters System Interface module, Waters 510 HPLC Pump, Waters 410 Differential 
Refractometer, Waters 700 Satellite Wisp, and four linear PL gel columns: 104, 105, 103 and 
100 Å connected in series). The flow rate of the chloroform was 1 ml/min and the injection 
volume was 200 µl. Before analysis, the samples were filtered through a 0.5 µm Millex SR 
filter. Monodispersed polystyrene standards were used for the calibration. More accurate 
structures of the prepared polymers were provided by 1H NMR. In the 1H NMR 
measurements, the samples were dissolved in chloroform-d1 (Fluka Chemica, deuteration 
degree not less than 99.8%) in 5-mm NMR tubes at room temperature. The sample 
concentration was about 1.0 % by weight. NMR spectra were recorded on a Varian XL-300 
NMR spectrometer working at 300.032 MHz for measuring protons. 
Melting temperatures (Tm) were measured by differential scanning calorimetry (DSC) 
(Mettler Toledo Star) in a nitrogen environment. Samples (5-10 mg) were heated twice from 
-100°C to 100°C, at a rate of 10°C/min, to ensure that their thermal histories were similar. 
The melting temperatures were evaluated from the first and the second heating scans. The 
morphology of the gold coated polymer films was visualized by environmental scanning 
electron microscopy (XL 30 ESEM TMP Microscope, FEI Co, Brno, Czech Republic). 
4.2.3 Preparation of PCL-O polymer films and discs 
In the in vitro studies, polymer films were formed by casting a polymer solution (1.6 g 
polymer in 50 ml of tetrahydrofuran) onto a circular teflon mold. The solvent was allowed 
to evaporate overnight at room temperature. The films were kept in a vacuum desiccator 
for 2 days before cutting them to 10 mg (thickness about 190-250 µm) pieces. 
In the in vivo and in vitro studies, discs of purified polymers were fabricated by 
compression molding (Carver press; Menomenee Falls, Wisconsin, USA). The used 
molding temperatures were 80°C for PCL, PCL-O: 8-88 (PCL block: 7500 g/mol), PCL-O: 4-
88 (PCL block: 3900 g/mol), and 125°C for PCL-O: 2-37 (PCL block: 1500 g/mol). Discs of 10 
mm diameter (thickness 400-600 µm, weight 40±8 mg) were punched from the produced 
films. Prior to implantation, the discs were disinfected by immersion in 70 % ethanol and 
washed with sterile 0.9% NaCl.  
4.2.4 Degradation and erosion of the PCL-O films in vitro 
Hydrolytic degradation (molecular weight decrease) and erosion (weight loss) of polymer 
films and discs were studied in phosphate buffer solution pH 7.4 (USP XXIV). Enzymatic 
degradation and erosion of the films were evaluated in simulated intestinal fluid (SIF; USP 
XXIV, pH 7.5, 1 % pancreatin). Pancreatin is a mixture of various enzymes such as amylase, 
lipase and proteases. The films and discs were incubated with 1.0 ml and 5.0 ml of 
incubation medium, respectively, in Eppendorf tubes by shaking the tubes at a frequency of 
100 strokes/min at 37°C (Grant OLS200, Cambridge, UK). The fresh SIF was changed daily 
and fresh buffer was changed once a week. Polymer films and discs were removed from 
incubation medium after predetermined periods. After incubation, the polymer films and 
discs were washed with deionized water and dried in a vacuum desiccator at room 
temperature for 2 days. The molecular weights of the dried films and discs were 
determined by SEC.  
     
The percent of molecular weight remaining and the percent of weight remaining were 
calculated by the Equation 1:   
 
M % = (M after/ M before) x 100 %                        (Eq. 1) 
 
Where M after is the Mw, Mn or weight of the dried polymer film or disc after incubation and 
M before is initial Mw, Mn or weight of the polymer film or disc.   
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4.2.5 Effects of enzyme inhibitors on erosion of PCL-O films 
The effects of the enzyme inhibitors on the erosion of PCL-O films were investigated in SIF. 
Several inhibitors for various classes of hydrolyzing enzymes were used. AEBSF, aprotinin 
and PMSF were used as general serine protease inhibitors. The chelators EDTA, EGTA and 
1,10-phenanthroline were used to inhibit metalloproteases and other divalent cation 
sensitive enzymes.  To further evaluate the possible role of metalloproteases, a general 
matrix metalloprotease inhibitor, GM6001, and a carboxypeptidase B inhibitor, EACA, were 
employed. The serine protease inhibitors, paraoxon-ethyl (diethyl p-nitrophenyl 
phosphate) and tetrahydrolipstatin (THL) were used as lipase and serine protease 
inhibitors.  
The incubation in SIF lasted for seven days as described above. Inhibitors were first 
added to the fresh SIF solution and after 15 min, the solution was placed on the polymer 
films (15 min was allowed for formation of enzyme-inhibitor complexes). Fresh solutions 
were changed once a day. After the end of the incubation, polymer films were washed with 
deionized water and dried in a vacuum for 2 days. In addition, films incubated with 
paraoxon-ethyl were washed twice with 70 % EtOH to remove adsorbed inhibitor from the 
polymer films.  
The stock solutions of enzyme inhibitors were prepared in water or DMSO, and divided 
into aliquots and stored frozen (-20°C). GM6001, 1,10-phenanthroline, THL and paraoxon-
ethyl were dissolved in DMSO. Other inhibitors were dissolved in water. Controls included 
DMSO or water at appropriate concentrations to evaluate if the solvents had affected the 
enzymatic reactions. The inhibitor concentrations were chosen based on the literature.   
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5 Effects of Block Length on the Enzymatic Degradation 
and Erosion of Oxazoline Linked Poly--Caprolactone  
 
 
 
Abstract: The aim of the study was to develop enzyme sensitive polymers for 
pharmaceutical applications. Thus, 2,2’-bis(2-oxazoline)-linked poly-ε-caprolactone (PCL-
O) polymers were synthesized  by using -caprolactone precursors with different molecular 
weights (Mn: 1500, 3900, 7500 and 12 000 g/mol), and the effects of PCL block length on 
enzymatic degradation and erosion (weight loss) of PCL-O films were studied. Solvent cast 
PCL and PCL-O films were incubated (22 days) in the presence of pancreatin (1%, pH 7.5), 
with and without enzyme inhibitors. In the absence of enzyme inhibitors, surface erosion of 
the PCL-O films occurred during the incubation, and the erosion of the PCL-O films 
increased in parallel with a decrease in the PCL block length. The presence of the lipase 
inhibitors, paraoxon-ethyl and tetrahydrolipstatin delayed the weight loss of the PCL-O 
films. These results indicate that lipase was mainly responsible for the enzymatic erosion of 
the PCL-O films. In comparison, practically no weight loss of the PCL or the PCL-O films 
was observed in phosphate buffer (pH 7.4) (28 days incubation). The results demonstrate 
that the studied -caprolactone based poly(ester-amide)s are enzyme sensitive polymers 
whose erosion rate can be controlled by the PCL block length. 
 
 
 
 
 
 
 
* Adapted from: Pulkkinen M, Malin M, Tarvainen T, Saarimäki T, Seppälä J, Järvinen K: Effects of 
block length on the enzymatic degradation and erosion of oxazoline linked poly--caprolactone 
Eur J Pharm Sci 31: 119-128, 2007. © Elsevier Ltd. 2007 
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5.1 INTRODUCTION 
The biodegradability and safety of polycaprolactone (PCL) and its copolymers are the key 
factors explaining the wide use of these polymers in medical and pharmaceutical 
applications. For example, they are used to create absorbable drug carriers and are 
incorporated into suture materials (Perrin and English 1997b). PCL is a hydrophobic, semi-
crystalline polymer which degrades by slow hydrolytic bulk degradation (Pitt 1990). The 
enzymatic degradation of PCL has also been investigated and three different bacterial 
lipases have been reported to accelerate the degradation of PCL (Fukuzaki et al. 1990; 
Mochizuki et al. 1995; Gan et al. 1997). 
PCL is highly permeable for low molecular weight molecules, which makes it suitable 
for diffusion controlled delivery of small drugs (Pitt 1990). However, many PCL 
formulations containing small molecules have shown incomplete and non-linear release 
(Buntner et al. 1998; Hombreiro Péres et al. 2000; Ubrich et al. 2004). Since PCL does not 
generate an acidic environment during the degradation process, PCL has been considered 
as a potential means of protein or antigen delivery (Jameela et al. 1997; Baras et al. 1999; 
Benoit et al. 1999; Youan et al. 1999; Jiang and Schwendemann 2001). Unfortunately, 
unmodified PCL may not be suitable for constant protein delivery because it has such a 
long degradation time and slow diffusion controlled release (Holland et al. 1986). Various 
copolymers and polymer blends of PCL have been prepared with lactide, ethylene oxide 
and glycolide to modify the polymer properties, especially the degradation rate (Pitt et al. 
1979; Pitt et al. 1981a; Malin et al. 1996; Perrin and English 1997b).  
Novel poly(ester-amide)s are an interesting way of modifying the polyesters. These 
polymers are composed of ester blocks which are linked through amide bonds. The 
combination of polyesters with amide bonds means that it is possible to produce polymers 
that exhibit enzyme enhanced degradation and erosion (Tsitlanadze et al. 2004a,b; Wang et 
al. 2005). If one creates surface eroding polymers, then it is possible to achieve a near 
constant release of drugs (Katti et al. 2002). If diffusion of drug molecules from the polymer 
matrix is much slower than erosion controlled drug release, then the drug release rate will 
be proportional to the surface area of device. Also, enzyme sensitive polymers can be used 
in targeted delivery as it should be possible to develop systems that will release drugs in 
one specific location. 
Recently, PCL was modified by introducing oxamide groups into the PCL main chain 
(Tarvainen et al. 2002b). In comparison to an unmodified PCL, pancreatin enhanced 
degradation and erosion of the modified polymer and macromolecule release from the 
polymer (Tarvainen et al. 2003). In the present study, 2,2’-bis(2-oxazoline)-linked PCLs 
were polymerized with different PCL block lengths. The aim of this study was to evaluate 
the effect of  the PCL block length on the enzymatic degradation and weight loss of 
oxazoline modified poly(ε-caprolactone) (PCL-O) films. Further, the enzymes responsible 
for the enhanced erosion of PCL-O films were examined.  
5.2 MATERIALS AND METHODS 
 The chemicals and general methods used in this study are described in Chapter 4.  
5.3. RESULTS AND DISCUSSION 
5.3.1 Polymer synthesis and characterization  
Six different PCL-O polymers with four PCL block lengths were successfully polymerized 
with relatively low polydispersities by chain-linking a caprolactone-based carboxyl 
terminated prepolymer using 2,2´-bis(2-oxazoline) as a chain extender (Figure 5.1). Figure 
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5.1 shows the chemical structure of PCL-O polymers. An example of the 1H NMR-spectrum 
is presented in Figure 5.2. Typical resonances of methylene groups of PCL and butanediol 
appear around 4.02 ( H a), 2.27 ( H e), 1.62 ( H b,d) and 1.35 (H c) ppm. Additional peaks 
due to PCL-O structure can be seen in several areas. The resonances of methylene groups of 
the succinoyl residue are found at 2.60 ( H g,f) ppm (Pó et al., 1995), and those of reacted 
oxazoline moieties are detected at 4.1-4.2 (H h) ppm and 3.5-3.6 (H i)  ppm (Kylmä et al. 
2001; Quaglio et al. 2002). The formation of an oxamide group due to the reaction between 
BOX and –COOH groups is believed to have caused small peak noticed at  7.7 (H j) ppm 
(Tuominen et al. 2002). Chloroform resonance is seen at 7.23 ppm. Details of the polymers 
are presented in Table 5.1. 
  
 
 
Table 5.1. PCL block lengths (Mn), molecular weights (Mn, Mw; g/mol), melting temperatures
a 
(Tm; °C) , crystallinities
b (cryst. %) and polydispersities (Mw/Mn) of studied polymer films.  
 
a Tm1 and Tm2 are melting points from the first and the second heating scan, respectively. 
b The degrees of crystallinity of PCL and PCL-O were calculated assuming proportionality to the 
experimental heat of fusion and reported enthalpy of fusion 139.5 J/g for 100% crystalline PCL (Crescenzi 
et al. 1972). 
c Determined from polymer 
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Figure 5.1. Structure of PCL-O. Symbols above the structure refer to 1H NMR signals in  
Figure 5.2. 
 
 
 
 
 
 
 
 
 
Polymer Code PCL block 
(Mn) 
Mw   Mn   Tm1/Tm2 
a  Cryst. 
% b 
   Mw/Mn
    
PCL-O 2-37 
2-52 
1500 
1500 
37 100 
52 000 
20 300      
24 500 
39 / 25 
39 / 26 
24 
28 
1.83 
2.12 
 4-88 
8-62 
8-88 
3900 
7500 
7500 
88 300 
62 100  
88 100 
46 200 
35 400 
46 100 
  62 / 52 c 
60 / 53 
63 / 52 
47  
50 
49 
1.91 
1.75 
1.91 
 12-86 12 000 86 100 45 000 62 / 54 49 1.91
PCL control - 67 600 41 500 65 / 56 52 1.63
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Figure 5.2. 1H NMR spectrum of PCL-O: 2-52. Signals are identified in Figure 5.1. 
 
 
5.3.2 Degradation and weight loss of the films in SIF without inhibitors 
The degradation (molecular weight decrease) (Table 5.2) and erosion (weight loss) (Figure 
5.3, Table 5.3) of solvent cast PCL-O and PCL films were studied in simulated intestinal 
fluid (SIF) (pH 7.5, pancreatin present) and phosphate buffer solution pH 7.4. No 
substantial weight loss was observed for PCL-O or PCL films during 28 days of incubation 
in phosphate buffer pH 7.4 (data not shown).  In SIF, the weight loss of PCL-O films was 
much faster compared to PCL (Figure 5.3).  Previously Gan et al. (1997) reported that the 
weight loss of PCL was not affected by the presence of porcine pancreatic lipase whereas 
pseudomonas lipase degraded polymer films completely within 4 days.   
PCL block length affected the weight loss rate of the PCL-O films in SIF as the weight 
loss of PCL-O films increased with a decrease in the PCL block length (i.e. an increase in the 
frequency of oxazoline link). However, when compared to a PCL-O polymer with a 
corresponding PCL block length (codes: 2-37 vs. 2-52; 8-62 vs. 8-88), the weight loss rate of 
PCL-O in SIF was not substantially affected by the molecular weight of the polymer. A 
complete erosion of the highly linked PCL-O polymers with PCL block length of 1500 g/mol 
(codes: 2-37 and 2-52) occurred in 12 days whereas the PCL-O with block length of 3900 
g/mol (code: 4-88) eroded completely in 22 days.  
During incubation, the pH of SIF decreased from 7.5 to 5.4 - 7.4. The pH of phosphate 
buffer solution pH 7.4 remained virtually constant during the incubation (pH 7.3 - 7.4). The 
weight loss of PCL-O films was not pH dependent between 5.0 - 7.4 (data not shown). 
The molecular weights of all of the studied polymers remained practically unchanged 
during incubation in SIF and phosphate buffer pH 7.4 (Table 5.2). These results indicate 
that surface erosion of PCL-O films in SIF had occurred. It has been proposed that large 
enzymes cannot penetrate into the polymer matrix and therefore enzymatic degradation of 
polyesters occurs mainly on the surface (Landry et al. 1996; Chawla and Amiji 2002). 
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Figure 5.3. Percentage of remaining weight of PCL-O and PCL films incubated in simulated 
intestinal fluid (SIF) at 37°C. Means ±S.D. are shown (n=3). 
 
 
In the present study, the degree of crystallinity decreased as a function of the decrease in 
the PCL block length (Table 5.1). The degree of crystallinity may affect the enzymatic 
degradation of the films. For example, a crystalline PCL polymer was reported to be more 
resistant to enzyme catalyzed degradation than an amorphous PCL polymer (Pitt et al. 
1981b). In the present study, the results shown in Table 2 cannot be explained merely by the 
crystallinity of the polymers, since erosion of PCL-O polymers with long PCL blocks (codes: 
8-62 vs. PCL) in SIF was faster than erosion of PCL although the crystallinity and molecular 
weights of the polymers were comparable (Table 5.1). 
The surface erosion of PCL-O films in SIF is demonstrated in the SEM pictures (Figures 
5.4 and 5.5). The PCL-O polymers with long PCL block lengths revealed rough surfaces 
after incubation in SIF (Figure 5.4:B,D; Figure 5.5:F). Interestingly, the PCL-O polymers 
with short PCL block length (codes: 2-37, 2-52) had smooth surfaces even after major 
weight loss in SIF (Figure 5.5:B,D). The PCL-O polymers with short PCL blocks are more 
flexible, because of their low crystallinity and low melting point (Table 5.1). Thus, they may 
erode evenly from the surface. It must be noted that the samples were dried before SEM 
analysis and therefore it is possible that films may have become deformed. The rough 
surfaces of PCL-O films with high crystallinities (codes: 4-88, 8-62, 8-88, 12-86) may be 
attributable to the higher erosion rate of amorphous regions. 
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Figure 5.4. SEM micrographs of PCL-O and PCL films before and after 18 or 22 days incubation 
in SIF. PCL-O: 8-62 film before (A) and after 18 days (B);  PCL-O: 8-88 film before (C) and 
after 18 days (D); PCL-O: 12-86 film before (E) and after 18 days (F); PCL film before (G) and 
after  22 days (H) incubation. Scale bar 100 µm. 
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Figure 5.5. SEM micrographs of PCL-O films before and after 5 days incubation in SIF. PCL-O: 
2-37 film before (A) and after 5 days (B); PCL-O: 2-52 film before (C) and after 5 days (D); 
PCL-O: 4-88 film before (E) and after 5 days (F) incubation. Scale bar 100 µm (A-D) or 50 µm 
(E-F). 
 
 
5.3.3 Weight loss of the films in SIF with inhibitors  
The highly linked PCL-O films (code: 2-52) were incubated in SIF for 7 days with various 
enzyme inhibitors. Table 5.3 shows that chelators (EDTA, EGTA, 1,10-phenanthroline) as 
well as known serine protease inhibitors with an ability to inhibit lipase (paraoxon-ethyl, 
THL) hindered the erosion of the PCL-O films whereas the other studied inhibitors 
apparently had little or no effect on the erosion rate.  
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Table 5.3. Relative weight lossa (RWL %) of PCL-O films (Code: 2-52) after 7 days’ incubation 
in SIF with inhibitors. (n ≥ 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a RWL %=(weight loss in SIF with inhibitor/weight loss in SIF without inhibitor)*100 
 
 
The enzymatic composition of porcine pancreatin is unclear but it is known to contain 
ribonuclease, amylase, lipase, and a variety of proteases such as the serine proteases, 
trypsin, chymotrypsin, elastase, as well as carboxypeptidases belonging to the 
metalloprotease class. In the present study, general serine protease inhibitors (AEBSF, 
aprotinin and PMSF) and metalloprotease inhibitors (EACA and GM6001) did not 
markedly affect the erosion rate of the PCL-O film in SIF. In contrast, paraoxon-ethyl and 
THL hindered the erosion of the PCL-O films. Paraoxon-ethyl (Gargouri et al. 1997) and 
THL (Schmid and Verger 1998) are known to be able to inactivate pancreatic lipases. Thus, 
our results indicate that the enzyme lipase is mainly responsible for the weight loss of PCL-
O films in SIF.  
In addition to paraoxon-ethyl and THL, the chelators (EDTA, EGTA, 1,10-
phenanthroline) delayed the erosion of the PCL-O films in SIF. When compared to EDTA 
and EGTA, 1,10-phenanthroline was slightly less efficient. The effect of the chelators on the 
erosion of the PCL-O films may be attributed to a decrease in concentration of divalent 
cations, mainly Ca2+ ions, in SIF. The levels of divalent ions, especially the Ca2+ ion 
concentration, are crucial for the activity of pancreatic lipase (Alvarez and Stella 1989; 
Zangenberg et al. 2001). EDTA and EGTA are well known calcium chelators. 1,10-
phenanthroline is more selective towards Zn2+ ions, but it also exhibits activity against other 
divalent cations. Previously 1,10-phenanthroline and EDTA have been found to strongly 
inhibit lipase isolated from pseudomonas fluorescens  (Makhzoum et al. 1996).  
 
Inhibitor 
 
 
Class of inhibitor 
 
Concentration 
 
RWL % 
   
AEBSF 
 
serine proteases 2 mM 90 
Aprotinin 
 
serine proteases 8 µM 102 
PMSF 
 
serine and cysteine 
proteases 
5 mM 107 
Paraoxon-ethyl 
 
serine proteases and 
lipase 
5 mM 0 
THL 
 
lipase  200 μM 4 
EDTA 
 
chelator 1 mM 4 
EGTA 
 
chelator 1 mM 5 
1,10-Phenanthroline 
 
chelator 1 mM 10 
GM6001 
 
metalloproteases 25 μM 99 
EACA 
 
metalloproteases and 
serine proteases  
2 mM 100 
Control (SIF) 
 
               - - 100 
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Recently, the enzyme enhanced degradation and erosion mechanisms of other 
poly(ester-amide)s have been reported.  Proteinase K enhanced the degradation of poly(L-
lactide)-poly(2-ethyl-2-oxazoline)-block-poly(L-lactide) and surface erosion of the polymer 
occurred  in the presence of enzyme (Wang et al. 2005). Further, poly(ester-amide)s made 
from hydrophobic α-amino acids, fatty diols and dicarboxylic acids exhibited more 
susceptibility to lipase and α-chymotrypsin catalyzed degradation than poly(DL-lactide), 
and the polymers showed surface erosion (Tsitlanadze et al. 2004a,b). These polymers 
degraded in rats over 3-6 months, but if lipase was included into the polymer matrix, then 
the polymers had completely degraded within one to two months.  
5.4 CONCLUSIONS 
The present results clearly demonstrate the enzyme sensitivity of PCL-O polymers. PCL-O 
polymers exhibited surface erosion in SIF and, the erosion rate could be controlled by the 
PCL block length. Further, it seems that lipase was mainly responsible for the weight loss of 
the films in SIF. The lipase enzyme is located in many tissues, such as macrophages, 
adipose tissue, heart, muscle, liver, lung and kidney (Mukherjee, 2003).  Therefore, it might 
be possible to utilize this enzyme sensitive degradation property in a variety of 
physiological target sites. Our results indicate that oxazoline linked poly-ε-caprolactone 
could serve as a useful material for pharmaceutical applications. 
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6 High-Performance Liquid Chromatography/ 
Electrospray Ionization Tandem Mass Spectrometry for 
Characterization of Enzymatic Degradation of 2,2’-Bis(2-
Oxazoline) Linked Poly--Caprolactone 
 
 
 
 
Abstract: This paper describes a straightforward and rapid on-line characterization using 
high performance liquid chromatography/electrospray ionization tandem mass 
spectrometry (HPLC-ESI-MSn) of the enzymatic degradation products of 2,2’-bis(2-
oxazoline) linked poly-ε-caprolactone (PCL-O). These new PCL-O polymers are expected to 
be used in a variety of pharmaceutical and biomedical applications since they are degraded 
enzymatically by surface erosion. PCL-O was polymerized in a three-step reaction and 
characterized by 1H-NMR and size-exclusion chromatography (SEC). Solvent cast polymer 
films were exposed to enzymatic degradation in phosphate buffer (pH 7.5, 1% pancreatin). 
The enzymatic degradation of the polymer produced a wide range of water soluble 
oligomers which were separated and identified by HPLC-ESI-MSn. Optimization of 
gradient HPLC method resulted in effective separation of the oligomers. Furthermore, 
specific structures of the oligomers were clearly identified by tandem mass spectrometry. 
According to these results, ester bonds seem to be most sensitive to enzymatic degradation 
and correspondingly, pancreatic lipase seems to be mainly responsible for the enzymatic 
erosion of the PCL-O films. This novel mass spectrometric method provides important 
knowledge about the enzymatic degradation process and structure of the polymer which is 
difficult to ascertain by other conventional methods.  
 
 
 
 
 
 
 
 
 
 
 
* Adapted from: Pulkkinen M, Palmgrén J, Auriola S, Malin M, Seppälä J, Järvinen K: High-
performance liquid chromatography/electrospray ionization tandem mass spectrometry for 
characterization of enzymatic degradation of 2,2’-bis(2-oxazoline) linked poly--caprolactone. Rapid 
Commun Mass Spectrom 22: 121–129, 2008. © John Wiley & Sons Ltd. 2007  
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6.1 INTRODUCTION  
Biodegradable aliphatic polyesters, such as polycaprolactone (PCL), have a wide variety of 
pharmaceutical and biomedical applications (Perrin and English 1997b). PCL is a promising 
material as it is safe, highly permeable to small compounds, and easy to process due to its 
low melting temperature and good solubility in common organic solvents. However, PCL 
degrades by slow hydrolytic bulk degradation, a property which is unfavourable for many 
applications. Various copolymers of PCL have been prepared with the aim of achieving 
faster degradation rates (Pitt 1990; Malin et al. 1996; Perrin and English 1997b; Barbato et al. 
2001) 
Poly(ester-amide)s are an interesting group of polymers since they can potentially 
enhance the slow degradation of PCL. The addition of amide links into polyester chain 
makes it possible to optimize material properties for different applications. Previously, we 
have demonstrated that a novel polymer, oxazoline linked poly-ε-caprolactone (PCL-O), is 
an enzyme sensitive surface eroding material (Tarvainen et al. 2003; Pulkkinen et al. 2007). 
Since it undergoes surface erosion it may be possible to achieve constant zero-order drug 
release from this novel material, a phenomenon which is difficult to achieve with bulk 
degradation. Furthermore, the susceptibly to enzymatic degradation may provide the 
possibility of targeted drug delivery with its various biomedical applications. However, the 
degradation mechanism must be clarified, since theoretically the produced fragments could 
cause different reactions at the application site.  
Previously, low molecular mass oligomers of enzymatic degradation products of 
aliphatic polyesters have been studied by high performance liquid chromatography 
(HPLC/UV) (Scherer et al. 1999), NMR (Abe et al. 1995; Li et al. 2002), atmospheric pressure 
chemical ionization mass spectrometry (APCI-MS) and electrospray ionization mass 
spectrometry (ESI-MS) with direct injection (Scandola et al. 1997; Focarete et al. 1999), and 
gas chromatography mass spectrometry (GC-MS) (Witt et al. 2001). However, these 
methods lack specificity and identification efficiency or they are only suitable for a small 
group of molecules. For example, direct injection of the sample into the mass spectrometer 
is difficult if the sample contains many different oligomers and other compounds such as 
proteins and salts. Other common methods, such as NMR, do provide an overall picture of 
the polymer but no specific structure information of individual polymer chains can be 
obtained with polydisperse samples. Although, theoretically it could be possible to separate 
the degradation products, the effort involved makes NMR time consuming and tedious. 
Furthermore, GC-MS is not suitable for non-volatile or thermolabile samples. 
Currently, HPLC-MS/MS technology is routinely applied in many analytical fields 
including polymer and oligomer characterization because of its high sensitivity, specificity 
and selectivity (Bourgue et al 2005; Haugen et al 2005; Liu et al. 2005; Zhong et al. 2005; 
Broberg 2007). The MSn fragmentation techniques can be utilized to achieve a more specific 
identification, thereby revealing the chemical nature of a polymer and its end groups 
(Jedliński et al. 1998). HPLC connected to fast atom bombardment mass spectrometry 
(HPLC-FAB-MS) and electrospray ionization mass spectrometry (HPLC-ESI-MS) have been 
shown to be effective tools for the analysis of the enzymatic degradation products of 
polyesters (Ando et al. 1998; Rizzarelli et al. 2004; van Leeuwen et al. 2007). Furthermore, 
the ESI ion source is a gentle method for detectable molecules and therefore it is well suited 
for analysing molecules with different properties. This paper describes a straightforward 
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and direct HPLC-ESI-MS/MS method for the characterization of enzymatic degradation 
products of the novel PCL-O polymer.  
6.2 EXPERIMENTAL 
The Chemicals and general methods used in this study are described in Chapter 4. 
6.2.1 Preparation of enzymatic degradation products  
The general sample preparation has been described in section 4.1.3. After incubation for 7 
days the degradation medium was collected and purified in an ultrafiltration tube 
(Nanosep 30K Omega, Pall Corporation, Ann Arbor, Michigan, USA) with centrifugation 
(Heraeus Biofuge, Fresco Kendro Laboratory Products, Osterode, Germany) at 10000 rpm 
for 10 min. Purified samples were analysed by HPLC-ESI-MSn. Control samples were 
processed as described above and included polymer films without pancreatin and plain 
pancreatin samples without films. Purified samples were analysed by HPLC-ESI-MSn.  
 
6.2.2 Liquid chromatography 
The HPLC system consisted of a Finnigan Surveyor (San Jose, CA, USA) MS pump (serial 
2.3) and a Finnigan Surveyor autosampler (serial 1.4) with a 20 µl injection volume. The 
tray temperature control and the column oven control were set to +20°C. The 
chromatographic separation was performed using a Xterra MS C8 reversed-phase column 
(2.1x150 mm, 3.5 m, Waters, Milford, MA, USA) with a flow rate of 200 µl/min. Solution A 
was water containing 5 mM ammonium acetate. Solution B was acetonitrile-water (90 % 
acetonitrile and 10 % of above-mentioned solution A). The gradient profile was water-
acetonitrile mixture; 2-90 % acetonitrile in 37 min, 90 % acetonitrile was running for 2 min. 
Thereafter the composition was returned to the initial conditions for 6 min before the next 
injection.    
 
6.2.3 Mass spectrometry 
A LTQ quadrupole ion trap mass spectrometer equipped with an electrospray ion source 
(ESI) (Finnigan LTQ, serial 1.0 SPI, San Jose, CA, USA) was used for the mass analysis. The 
ionization was performed in the positive ion mode and full scan mass spectra from m/z 200 
to 2000 were measured. Furthermore, MS/MS and MS3 spectra were acquired based on 
selected reaction monitoring (SRM) of the most intense product ions (m/z). The charge state 
of the ions was determined in the ZoomScan mode. Ion source collision induced 
dissociation (CID) was used for some specified scan events. Mass spectrometric parameters 
were optimized using the semi-automatic methods in the LTQ instrument. The optimized 
conditions and parameters were as follows: capillary temperature 250°C, spray voltage 4.0 
kV, sheath gas flow rate 27 (arbitrary unit), capillary voltage 24 V, and tube lens 185 V. In 
the ion trap, the relative collision energy was 30 % for all the selected ions. Data were 
processed using the Xcalibur software package version 1.4 SRI. 
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6.3 RESULTS AND DISCUSSION  
The novel 2,2’-bis(2-oxazoline) linked poly-ε-caprolactone polymer (PCL-O) was 
successfully polymerized and characterized by size-exclusion chromatography (SEC) and 
NMR spectroscopy. More detailed results are shown in Table 6.1. The chemical structure of 
the PCL-O polymer is shown in Figure 6.1. In this study, the water soluble oligomers 
produced by enzymatic degradation of PCL-O were characterized with the newly 
developed HPLC-ESI-MS/MS method.  
 
 
 
Table 6.1. Molecular weight, polydispersity and composition of the studied polymer (PCL-O). 
 
 
 
 
 
 
BOX: 2,2’-bis(2-oxazoline), SA: succinic anhydride, CL: ε-caprolactone, BD: 1,4-butanediol  
a Molar composition of the polymer determined by 1H-NMR 
b Mw and Mn determined by SEC 
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Figure 6.1. Chemical structure of PCL-O. The proposed lipase-catalyzed degradation sites 
are shown by arrows. Symbols below the structure refer to Table 6.2. 
 
6.3.1 Liquid chromatography 
A gradient method with a reversed-phase column was chosen for the analysis. Figure 6.2 
shows the base peak chromatogram of the sample after enzymatic treatment. As can be 
seen in the chromatogram, a complex mixture of degradation products was separated 
effectively within a 30 min run time. The acetonitrile-water-ammonium acetate solution, the 
tray temperature control, and the column oven control ensured a stable analytical run. 
Potential contamination problems in the column or autoinjector were minimized by using a 
high organic solvent content both in the autoinjector and in the mobile phase. After the 
samples had been analysed, pure water samples did not display any traces of carry-over. 
 
 
 
 
 
 
 
 
Polymer Composition a Mw (g/mol) 
b Mn (g/mol)
 b Mw/Mn 
BOX/SA/CL/BD 1/2/9/1 52 000 24 500 2.1 
      BOX                                    SA                         CL                              BD                                CL                            SA            
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Figure 6.2. HPLC/ESI base peak chromatogram of the polymer sample after 7 days enzymatic 
treatment in simulated intestinal fluid (pH 7.5, 1% pancreatin, 37°C). The m/z values of base 
peaks are marked on the chromatogram. 
 
6.3.2 Mass spectrometry 
Mass spectrometry is a suitable alternative for the analysis of polymer and degradation 
product samples. The mass spectrometric analysis detects a variety of fragments of 
polymers as sodium or potassium -cationized adducts (Jedliński et al. 1998; Haugen et al. 
2005; Liu et al. 2005; Borberg 2007). However, a very low abundance of product ions or less 
informative product ions have been acquired from sodium -cationized precursor ions in the 
tandem mass spectra. In this study, the oligomers were detected as protonated molecules 
[M+H]+ and abundant ammonium adducts [M+NH4]+. The positive mass spectrum of 
selected oligomer is shown in Figure 6.3a. The presence of ammonium acetate enhanced the 
signal of oligomers through the suppression of other cationized species such as Na+ and K+ 
adducts. We observed that ion source CID was suitable for ammonium adducts [M+NH4]+, 
which further intensified the signal of the protonated molecules [M+H]+. The protonated 
molecules were selected as precursor ions and product ions were detected with the MS/MS 
mode. Furthermore, the most or second most intense product ions were used for the MS3 
experiments. ZoomScan analysis, which is a high resolution MS scan type available in the 
LTQ instrument, indicated that the oligomers were being detected as single charged 
molecules. Some degree of ion source fragmentation of the biodegradation products was 
noted during the measurements as can be seen in Figure 6.3a. 
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Figure 6.3. Mass spectra of some selected degradation products: (a) MS spectrum of m/z 719 
at retention time 19.78 min; (b) MS2 spectrum of m/z 719 at retention 19.78 min; and (c) MS2 
spectrum of m/z 719 at retention time 21.56 min. 
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6.3.3 Degradation product characterization  
The main enzymatic degradation products (> 5% intensity of the largest peak) are shown in 
Table 6.2. Furthermore, high sensitivity of ESI-MS/MS permitted the detection about 80 
different oligomers with a size range of m/z 305-1349 (data not shown). As can be seen in 
Table 6.2, the degradation products of PCL-O contain structural units of 100, 114 and 158, 
which are related to succinic anhydride, caprolactone and amide group, respectively. 
Correspondingly, the same mass differences were observed in MS2 and MS3 spectra 
(Figures 6.3-6.5). In contrast to the polymer-enzyme samples, similarly treated polymer 
samples without enzymes did not reveal any significant amounts of degradation products. 
This result corresponds with the previous result where hydrolysis of PCL-O films in 
phosphate buffer solution (pH 7.4) without the presence of enzymes did not evoke any 
substantial weight loss during 7 days (Pulkkinen et al. 2007). Moreover, plain enzyme 
samples did not contain similar peaks as the polymer sample. 
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Figure 6.4. MS2 spectrum of m/z 347 at retention time 14.26 min. 
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Figure 6.5. MS2 and MS3 spectra of some selected degradation products: (a) MS2 and (b) MS3 
spectra of m/z 605 at retention time 17.28 min. (c) MS3 spectrum of m/z 505 at retention time 
18.32 min. 
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Table 6.2. Proposed structures of main biodegradation products.  
 
M+H Structure Ret (min) 
977.6 SA-BOX-SA-BOX-SA-(CL)3 20.88 
863.5 CL-SA-BOX-SA-BOX-SA-CL 17.46 
863.5 CL-SA-BOX-SA-BOX-SA-(CL)2 18.93 
833.6 SA-BOX-SA-(CL)4 23.51 
763.5 BOX-SA-BOX-SA-(CL)2 20.05 
749.4 SA-BOX-SA-BOX-SA-CL 14.95 
719.4 CL-SA-BOX-SA-(CL)2 19.78 
719.4 SA-BOX-SA-(CL)3 21.56 
689.5 SA-(CL)5 26.53 
677.5 SA-BOX-SA-(CL)2-BD 23.69 
649.3 BOX-SA-BOX-SA-CL 15.67 
619.4 BOX-SA-(CL)3 22.98 
605.3 CL-SA-BOX-SA-CL 15.74 
605.4 SA-BOX-SA-(CL)2 17.28 
589.6 (CL)5 29.01 
575.4 SA-(CL)4 23.18 
563.5 BD-SA-BOX-SA-CL 16.97 
563.4 SA-BOX-SA-CL-BD 19.07 
533.5 BD-SA-(CL)3 25.35 
505.3 BOX-SA-(CL)2 18.32 
491.3 SA-BOX-SA-CL 12.41 
475.3 (CL)4 25.09 
461.5 SA-(CL)3 19.14 
391.3 BOX-SA-CL 12.78 
361.4 (CL)3 20.29 
347.4 SA-(CL)2 14.26 
BOX: 2,2’-bis-oxazoline, SA: succinic anhydride, CL: ε-caprolactone, BD: 1,4-butanediol. 
Structures are shown in Figure. 6.1. 
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In the base peak chromatogram, m/z 347 was the smallest detected oligomer of the main 
degradation products. When this protonated oligomer was selected as the precursor ion, 
the MS2 measurement detected product ions of m/z 115, 229, and 329 (Figure 6.4), indicative 
of the cleavage of monomers and the loss of water. This was evidence that the oligomer of 
m/z 347 contained the structural units (monomers) of 100 and 114 Da. The proposed 
product ions from MS2 spectrum of degradation product m/z 347 are shown in Table 6.3.  
 
 
Table 6.3. Proposed main fragments of the MS2 spectrum of biodegradation product m/z 347 
(ret. 14.26 min).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, great numbers of similar product ions were observed in MS2 and MS3 
spectra of different oligomers reflecting the character of the polymer. Also, similar MS3 
spectra were detected from different oligomers, which confirmed that these oligomers 
contained the same structure (Figure 6.5: b,c). As anticipated, similarities between MS2 and 
MS3 spectra of the same parent ion were noted (Figure 6.5:a,b). MS3 spectra were used for 
further identification because they revealed a greater number and smaller fragment ions 
than MS2 (Figure 6.5:a,b). In addition, MS3 spectra produced important knowledge of the 
structure as it revealed the end groups and the location of the different monomers in the 
various oligomer chains.  
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Table 6.4. Proposed main fragments of the MS2 spectrum of biodegradation product m/z 719 
(ret 21.56 min).  
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Isomeric oligomers with the same molecular weight but with different sequences were 
identified by their retention times and mass spectra (Figure 6.3: b,c). Clearly, these different 
oligomers had the same monomer composition but a different sequence. For example, ions 
m/z 619 and 601 can be seen in the spectra of m/z 719 with a retention time of 21.56 min 
(Figure 6.3: c). These ions are produced because of the cleavage of succinic group (-100) and 
water. The proposed structures of the main ions seen in MS2 spectrum of m/z 719 (ret 21.56 
min) are shown in Table 6.4. Some of these ions (m/z 619, 601, 443 and 343) are missing 
from the spectrum of isomeric oligomer m/z 719 at a retention time of 19.78 min (Figure 
6.3:b).  
Our earlier results suggested that lipase is mainly responsible for the enzymatic erosion 
of the PCL-O films incubated in simulated intestinal fluid (SIF; USP XXIV, pH 7.5, 1 % 
pancreatin) (Pulkkinen et al. 2007). If one considers the structure of the present main 
degradation products, it can be noted that the butanediol element is rarely seen in the main 
degradation products (Table 6.2). This is probably due to the ability of lipase to degrade 
water soluble fragments and the affinity of lipase against butanediol. It has been 
demonstrated that lipase is capable of catalysing the degradation of water soluble 
oligomers from polyesters, and therefore the butanediol terminated oligomers were rapidly 
hydrolyzed by lipase (Haugen et al. 2005). In contrast to butanediol, amide bonds remained 
intact in the PCL-O oligomers during enzymatic degradation (Table 6.2.). According to 
these results, it is proposed that ester bonds are the most probable sites for cleavage in the 
PCL-O chain (Figure 6.1). These results confirm the important role of lipase in the 
enzymatic degradation process of PCL-O as lipase primarily cleaves ester bonds.  
NMR revealed the molecular composition of the polymer (Table 6.1). The results from 
the polymer before enzymatic degradation (NMR) and the detected soluble degradation 
products (HPLC-ESI-MS) are as would be expected when one compares the molar ratios of 
polymer and structure of oligomers. It can be calculated from the NMR data that 
approximately one polymer block consists of 9 caprolactone units (Figure 6.1, n+m) as the 
molar ratio of PCL-O is 1/2/9/1 (bis-oxazoline/succinic anhydride/caprolactone/butanediol). 
These short caprolactone sequences are linked with butanediol which means that an 
average of 4-5 caprolactone units are connected together. The main biodegradation 
products displayed caprolactone chains with 4-5 units, but no higher number of connected 
caprolactones could be detected. On the other hand, shorter caprolactone chains were 
observed in many oligomers. This is probably due to the activity of lipase to break down 
bonds between caprolactone units. In addition, NMR provides an overall picture of the 
polymer, which means that shorter caprolactone chains presumably are present in the 
polymer matrix although the calculated molar composition indicated a higher value. 
Furthermore, as molecules have to be charged prior to measurement, some oligomers (e.g. 
those containing amide groups) may show a better affinity for protons and other cations 
and this results in their higher intensities.  
In comparison to NMR, the HPLC-ESI-MS/MS technique enables the direct identification 
of various polymer fragments including the detection of isomeric structures and end 
groups. It can be seen that this novel mass spectrometric method revealed the structure of 
the hydrolyzed oligomers produced by enzymatic degradation. Moreover, it seems evident 
that some polymer fragments contained two oxamide groups close to each other. In terms 
of polymer properties and polymerization this is new important information, which is 
difficult to obtain by using conventional techniques.  
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6.4 CONCLUSIONS  
A new direct and simple procedure for the analysis of enzymatic degradation products of 
the novel PCL-O polymer using HPLC-ESI-MS/MS was developed. Pancreatic enzymes 
produced about 80 detectable oligomers of the PCL-O polymer. The results are evidence 
that pancreatic enzymes cleaved mainly ester bonds and thus were largely unable to cleave 
the amide bonds in the polymer chain. These results are in accordance with our earlier 
study indicating that lipase which is present in pancreatin is mainly responsible for the 
enzymatic degradation of PCL-O. Mass spectrometric results provided new important 
information of the enzymatic degradation process and the structure of the polymer. 
Furthermore, the results revealed that mass spectrometry can be effectively used to provide 
more specific knowledge of the structure of polymers after enzymatic degradation. 
Especially when combined with the conventional NMR, the new HPLC-ESI-MS/MS method 
provides crucial structural information which can be missed if these methods are not used 
together.  
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7 In Vivo Implantation of 2,2’-Bis(Oxazoline)-Linked 
Poly--Caprolactone: Proof for Enzyme Sensitive Surface 
Erosion and Biocompatibility  
 
 
 
 
Abstract: Previously, we have demonstrated that 2,2-bis(2-oxazoline) linked poly-ε-
caprolactone (PCL-O) is degraded in vitro enzymatically by surface erosion which could 
enable the novel use of this material for drug delivery and other biomedical applications. In 
this study, degradation, erosion (weight loss) and toxicity of PCL-O poly(ester-amide)s 
were evaluated in vivo. PCL and three PCL-O polymers with different PCL block lengths 
(Mn: 1500, 3900, 7500 g/mol) were melt-pressed in the form of discs and implanted 
subcutaneously in Wistar rats (dose ~340 mg/kg) for 1, 4 and 12 weeks. With implantation 
for 12 weeks, up to 16.5 % weight loss of polymer discs was measured for the most 
extensively linked PCL-O polymer (block length 1500 g/mol) whereas practically no weight 
loss was observed with the other polymers. NMR, DSC and SEC studies as well as SEM 
micrographs before and after implantation and in vitro hydrolysis studies indicate that 
enzyme based surface erosion of PCL-O polymers occurred in vivo. The in vivo evaluation 
based on results from hematology, clinical chemistry and histology of the implantation area 
and main organs (i.e. heart, lung, liver, kidney, spleen and brain) demonstrated that PCL-O 
polymers are biocompatible and safe, enzyme-sensitive biomaterials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted from: Pulkkinen M, Malin M, Böhm J, Tarvainen T, Wirth T, Seppälä J, Järvinen K: In vivo 
implantation of 2,2’-bis(oxazoline)-linked poly-ε-caprolactone: Proof for enzyme sensitive surface 
erosion and biocompatibility. Eur J Pharm Sci 36: 310-319, 2009 
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7.1 INTRODUCTION  
Poly-ε-caprolactone (PCL) is a widely used biodegradable polymer which has both 
pharmaceutical and biomedical applications (Perrin and English 1997b). In addition to 
delivery of small drug molecules (Pitt 1990), PCL has been recently evaluated for potential 
use in protein and antigen delivery (Baras et al. 1999; Benoit et al. 1999; Youan et al. 1999), 
because it does not generate an acidic environment during degradation. However, slow 
hydrolytic bulk degradation of PCL (Pitt 1990), hinders the development of controlled drug 
delivery systems. Thus, PCL has been extensively modified by using copolymerization or 
polymer blends in attempts to achieve controllable and faster degradation rate (Pitt et al. 
1979; Malin et al. 1996; Perrin and English 1997b).  
Poly(ester amide)s are an interesting group of polymers for PCL modification, because 
they have been demonstrated to display an enzyme sensitive degradation profile 
(Tsitlanadze et al. 2004a,b). The addition of amide groups into the polyester chain enables 
tailoring of polymers for a variety of applications such as controlled and targeted drug 
delivery as well as other biomedical applications. We have previously shown that 2,2-bis(2-
oxazoline) linked poly-ε-caprolactone (PCL-O) degrades in vitro by enzyme enhanced 
surface erosion and macromolecule release is accelerated due to an enzyme susceptible 
property (Tarvainen et al. 2003; Pulkkinen et al. 2007). Furthermore, the erosion rate of 
PCL-O can be modified by using different lengths of PCL block, i.e. polymers with shorter 
PCL block show faster erosion rates.  
Lipase was found to be mainly responsible for the fast in vitro enzymatic erosion of PCL-
O. (Pulkkinen et al. 2007, 2008). Since lipase is found in many organs, it was postulated that 
these polymers would likely to be degraded in the body. However, little is known about the 
functionality and biocompatibility of this group of polymers in vivo. Therefore, the aim of 
this study was to evaluate the in vivo degradation, erosion and biocompatibility of PCL-O 
polymers over 12 weeks of subcutaneous implantation in rats. Three PCL-O polymers with 
different PCL block lengths were evaluated after their processing into discs.  
7.2 EXPERIMENTAL SECTION  
The materials and general methods used are described in Chapter 4. 
7.2.1 In vivo degradation, erosion and biocompatibility 
Adult female Wistar rats (190-250g) free of parasites, mycoplasma, fungi, viruses and 
potentially pathogenic bacteria were obtained from National Laboratory Animal Center in 
Kuopio, Finland. Animal studies were approved by the Animal Ethics Committee at the 
University of Kuopio (current University of Eastern Finland). The biological evaluation of 
polymers followed ISO 10993 standard (Part 6: tests for local effects after implantation, Part 
11: Tests for systemic toxicity) with minor modifications. The test periods were 1, 4 and 12 
weeks in accordance with the recommended short-term implantation procedure 
(subchronic toxicity).  
Discs of PCL and PCL-O polymers were implanted subcutaneously into the backs of 
adult female Wistar rats (age 12-15 weeks; 12 weeks old rats for 4 weeks and 12 weeks 
implantation, and 15 weeks old rats for 1 week implantation). Rats were housed in groups 
of 3-4 in metal cages. Animals were transferred into a new group at least 7 days before 
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implantation to ensure compatibility. During the experiment, the rats had free access to 
food and water.  
Rats were anesthetized by intraperitoneal injection of Ketalar/Domitor solution 75 mg/kg 
and 0.5 mg/kg, respectively. The back of each rat was shaved with a hair clipper and 
cleaned using Betadine solution (Leiras, Finland) and the weight of the rat prior to 
implantation was measured. Two small incisions were made on both sides of the dorsal line 
and subcutaneous pockets were formed by blunted scissors. The sharp edges of the discs 
were rounded before implantation. Prior to implantation, the polymer discs were purified 
by immersion in ethanol (70 %) and saline (0.9 %). Every animal received two similar 
polymer discs (approximately 80 mg polymer/animal, corresponding to ~340 mg/kg). Sham 
surgery (without the implant) was conducted on the reference group. After implantation, 
the incisions were closed with Vicryl® sutures 4-0 (Ethicon, UK). Immediately after the 
operation, the rats were given subcutaneously analgesic carprofen (5 mg/kg) and the 
reversal agent, atipametzole (0.25 mg/kg). The recovery of the animals was monitored daily 
including evaluation of coat condition (wound condition), posture, respiration, tremors, 
convulsions and behavior. During the study, the rats were weighed once a week. 
Rats were sacrificed after 1, 4 and 12 weeks by CO2 and blood samples were taken by 
heart puncture. Clinical chemistry (enzyme and ion measurements) and haematological 
(cell counts) parameters were analysed from blood samples (Research Institute of Public 
Health, Kuopio, Finland). Cell counts were measured from K2-EDTA tubes (Microtainer®, 
BD, Helsinki, Finland); plasma samples containing lithium heparin (Microtainer®) were 
used for enzyme and ion measurements. The polymer discs were removed, rinsed with Mq-
water, dried and the molecular weights (degradation) and weight losses (erosion) were 
measured.  
The local implant site and important organs were excised for histological evaluation. The 
collected organs included heart, kidneys, spleen, liver, lung and brain (only after 12 weeks 
implantation). Weighed organs and tissue samples were fixed in 10 % neutral buffered 
formalin. The samples were then embedded in paraffin and dehydrated by isopropanol 
processing. Thin layers (~5µm) were cut from the sample with a microtome and the 
samples were fixed by hematoxylin-eosin staining. The histological evaluation was 
performed under light microscopy.  
In the histopathological examination, any reactive inflammatory changes were evaluated 
using grade of 0-3, representing no remarkable, minimal, mild and marked changes, 
respectively. The thickness of the inflammatory layer was expressed as the average of two 
measurements using a micrometer, and from the microscopical evaluation of histological 
samples using a scale bar.  
7.3. RESULTS AND DISCUSSION 
7.3.1 Polymer degradation and erosion 
PCL and three PCL-O polymers with different PCL block lengths were successfully 
synthesized and melt-pressed into polymer discs. The properties of the polymer discs 
before in vivo and in vitro studies are shown in Table 7.1. The degradation and erosion of 
the PCL-O polymers were evaluated after in vitro (phosphate buffer pH 7.4, 37°C) and in 
vivo studies (s.c. in rats) by DSC, NMR, SEC, SEM imaging and the rate of weight loss. 
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Polymer discs were subcutaneously implanted in rats for 1, 4 and 12 weeks. The erosion 
(weight loss) of PCL-O discs in vivo increased in conjunction with a decrease in PCL block 
length (Figure 7.1:A). However, it must be noted that only PCL-O: 2-37 (the polymer with 
the shortest block length) had eroded to any significant degree 12 weeks after implantation. 
When compared to in vivo implantation, no substantial weight loss was observed for any 
PCL-O or PCL discs during 12 weeks of incubation in phosphate buffer (Figure 7.1:B).  
 
Table 7.1. PCL block lengths (Mn), molecular weights (Mn, Mw; g/mol), glass transition 
temperatures (Tg;; °C), melting temperatures
a (Tm; °C) , crystallinities
b (cryst. %) and poly-
dispersities (Mw/Mn) of initial polymer discs.  
 
a Tm1 and Tm2 are melting points from the first and the second heating scan, respectively. 
b The degrees of crystallinity of PCL and PCL-O were calculated assuming proportionality to the 
experimental heat of fusion and reported enthalpy of fusion 139.5 J/g for 100% crystalline PCL (Crescenzi 
et al. 1972). 
 
The weight loss rate of PCL-O: 2-37 (Figure 7.1) was much faster than its degradation 
rate in vivo (Figure 7.2) during the 12 weeks’ implantation. In addition, NMR results did not 
defect any remarkable changes due to implantation (Figure 7.3). These results demonstrate 
the contribution of surface erosion in vivo. SEM micrographs of the discs after implantation 
for 12 weeks confirm the surface erosion of the PCL-O: 2-37 while the surface morphology 
of other polymer discs remained practically unchanged ovar this period (Figure 7.4). 
Furthermore, in vivo enzyme sensitivity of PCL-O: 2-37 was confirmed as the weight loss 
rate was much faster in vivo than in vitro (phosphate buffer pH 7.4, 37°C). 
Changes in the molecular weights of PCL-O discs as a function of time were comparable 
in vitro and in vivo (Figure 7.2). However, the slightly slower in vivo degradation rate was 
noted for PCL-O polymers with shorter PCL block lengths (PCL-O: 2-37 and 4-88). The 
slower degradation rate in vivo may be explained by lower water availability in 
subcutaneous tissue compared to in vitro degradation conditions.  
Practically, no change in melting temperatures (Tm), glass transition temperatures (Tg) 
and the crystallinity of the polymer discs occurred during in vitro or in vivo studies (Table 
7.2). Though a slight increase in the crystallinity of the polymers was noted for PCL and 
PCL-O (Codes: 8-88 and 4-88) polymers in vivo. In addition, no substantial change in 
polymers structure could be detected by H-NMR during the 12 week study either in vitro or 
in vivo. As an example, Figure 7.3 shows NMR spectra of PCL-O: 2-37 before and after 12 
weeks of implantation. 
 
 
 
   
 
Polymer Code PCL 
block 
(Mn) 
Mw   Mn  Tg  Tm1/Tm2
a  Cryst. 
% b 
Mw/Mn 
         
  PCL (control) - 102 800 63 000 -63 67 / 57 55 1.6
  PCL-O 8-88 7500 88 500 47 200 -59 61 / 53 52 1.9
 4-88 3900 85 600 44 400 -57 59 / 51 48  1.9 
 2-37 1500 33 400 18 200 -45 40 / 30 24 1.8
49 
 
 
A) 
 
 
B) 
 
Figure 7.1.  Percentage of remaining weight of the polymer discs after s.c. implantation in rats 
(A) and incubation in phosphate buffer pH 7.4 at 37ºC (B). Means ± S.D. are shown (n=4-5 for 
picture A, n=3 for picture B). 
 
Earlier we demonstrated surface erosion of PCL-O polymers in an in vitro enzyme 
solution (Pulkkinen et al. 2007). In comparison with these earlier in vitro results, it can be 
noted that the erosion rate of the polymers in vivo was much slower. For example, PCL-O: 
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2-37 and 4-88 polymers had completely eroded in simulated intestinal fluid during 12 and 
22 days, respectively. However, in this study PCL-O: 2-37 eroded 16.5 % and no substantial 
weight loss was observed for PCL-O: 4-88 after 12 weeks of implantation. These results may 
be associated to the lower enzyme activity and poorer water availability in the in vivo 
situation. We reported previously that the lipase enzyme was mainly responsible of erosion 
of PCL-O polymers in simulated intestinal fluid (Pulkkinen et al. 2007, 2008). Lipase is 
known to be present in subcutaneous tissue and macrophages (Mukherjee 2003). 
 
 
 
A) 
 
B) 
 
 
 
 
 
C) 
D) 
Figure 7.2. Molecular weights of the polymer discs either after s.c. implantation in rats (A and 
B) or incubation in phosphate buffer  pH 7.4 at 37ºC (C and D). Means ± S.D. are shown    
(n=3-4). 
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Table 7.2. Melting (Tm) and glass transition (Tg) temperatures and crystallinity (Cryst. %) of 
polymer discs after implantation in rats or incubation in phosphate buffer pH 7.4 at 37ºC. 
 
Sample  Time 
(weeks) 
Tm2
a / °C Tg / °C Cryst. % 
 
PCL      
 
0 57 -63 55 
 in vitro 4 58 -61 54 
  12 58 -62 54 
      
 in vivo 4 58 -61 59 
  12 59 -62 59 
PCL-O  
8-88 
 
0 53 -59 52 
 in vitro 4 55 -57 51 
  12 54 -58 52 
      
 in vivo 4 54 -58 52 
  12 54 -59 54 
PCL-O  
4-88  
 
0 51 -57 48 
 in vitro 4 53 -56 48 
  12 52 -54 49 
      
 in vivo 4 53 -55 48 
  12 51 -57 53 
PCL-O  
2-37 
 
0 30 -45 24 
 in vitro 4 28 -47 25 
  12 28 -47 24 
      
 in vivo 4 29 -45 24 
  12 29 -46 24 
a Tm2 from the second heating scan 
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Figure 7.3. 1H NMR spectrum of PCL-O: 2-37 before (A) and after (B) 12 weeks’ s.c. 
implantation in rats. 
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Figure 7.4. SEM micrographs of PCL and PCL-O polymer discs before (left) and after 12 weeks 
incubation in buffer (pH 7.4 at 37°C) (middle) or 12 weeks’ s.c. implantation in rats (right). 
Scale bar 100 µm. 
 
 
7.3.2 Biocompatibility of polymers 
The biocompatibility of PCL-O polymers was compared to well known safe polymer PCL 
and was studied in rats during 12 weeks of implantation. Animals with sham surgery were 
used as controls. The systemic toxicity of polymers was assessed from the body weight of 
the animals, by a pathological examination of implantation sites and organs, and from the 
basic values of hematology and clinical chemistry as well as daily monitoring (behavior and 
condition) of animals. Local toxicity was evaluated from histological assessment of 
implantation site and the size of fibrous capsule around implant.  
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Figure 7.5.  Weight gain of the female Wistar rats during the 12 weeks’ implantation.  
Means±S.D. are shown (n = 3). 
 
 
 
 
Figure 7.6. Light micrographs of PCL (A) and PCL-O: 2-37 (B) implantation sites at 12 weeks’ 
post s.c. implantation in rats. Locations of polymer (Polymer), fibrous capsule (FC) and fat 
tissue (F) are shown. Original magnification: 100×. 
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All of the animals remained healthy during the experiment as evidenced by daily 
monitoring and by following at weekly intervals the body weight gain after implantation 
(Figure 7.5). A slight decrease in body weight gain was seen for PCL-O:2-37 animals 
between 7-9 weeks after implantation, but the reason for this phenomenon remains 
unknown. However, after 12 weeks there were no substantial differences between sham 
control and PCL-O: 2-37 animals. 
Pathological examination of implantation sites and organs after implantation for 1, 4 or 
12 weeks did not reveal any clear evidence of polymer associated toxicity (Figure 7.6, Table 
7.3). Furthermore, though some deviation in relative organ weights of animals can be seen 
in Table 7.4, the values are within the range of normal deviation. Fibrous capsules around 
the implant rapidly appeared and their thickness increased with time (Table 7.3), but PCL-
O polymers were not significantly different from their PCL counterparts in this respect. 
Micrometer based measuring of fibrous capsule was confirmed by histological 
measurement using optical microscope; results were comparable with these methods. It 
should be noted that gaps between fibrous capsule and other tissue are artifacts caused by 
processing of the sample (Figure 7.6). Similarly, the polymer discs are not themselves 
visible in Figure 7.6 since they had been removed from the cavity of the fibrous capsule 
during sample preparation.  
Basic values of hematology and clinical chemistry of rats after implantation for 12 weeks 
are shown in Table 7.5. Although some small deviation in the values of PCL-O polymers 
compared to PCL or sham controls can be observed, all values were in the range of normal 
reference data for Wistar rats. In addition, the values after 1 and 4 weeks of implantation 
did not reveal any marked changes as compared to control animals (data not shown). The 
only differences from our reference data were the lower amount of lymphocytes after 1 
week of implantation and the higher amount of monocytes at all time points. However, no 
significant change could be seen when groups were compared, indicating that the 
difference was probably caused by a different analysis method or different housing 
conditions of the animals.  
7.4 CONCLUSIONS 
This study confirmed in vivo enzyme sensitive surface erosion of novel poly(ester amide)s 
based on 2,2-bis(2-oxazoline) linked poly(ε-caprolactone). After implantation from one to 
twelve weeks, hematology, clinical chemistry and histological data did not reveal any 
marked toxicity attributable to the oxazoline linked polymers as compared to control 
animals. These results suggest that PCL-O polymers are biocompatible and safe materials 
showing enzyme sensitive surface erosion in vivo. In addition, the erosion rate of PCL-O can 
be controlled by the PCL block length, which may provide new possibilities for 
pharmaceutical and biomedical applications. 
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Table 7.4. Relative organ weights for female Wistar rats after 12 weeks s.c. implantation of 
PCL and PCL-O discs (Means ± SD are shown, n=3). 
 
 PCL PCL-O:8-88 PCL-O:4-88 PCL-O:2-37 Control 
Body weight (g)  276.3 ± 18.3 274.6 ± 16.1 273.4 ± 16.2 262.4 ± 24.6 267.5 ± 10.8 
Liver (g%) 3.73 ± 0.07 3.49 ± 0.29 3.41 ± 0.19 3.43 ± 0.11 3.39 ± 0.09 
Kidneys (g%) 0.60 ± 0.01 0.61 ± 0.02 0.61 ± 0.06 0.68 ± 0.04 0.63 ± 0.06 
Lungs (g%) 0.54 ± 0.07 0.55 ± 0.08 0.57 ± 0.05 0.60 ± 0.08 0.52 ± 0.11 
Heart (g%) 0.30 ± 0.02 0.33 ± 0.03 0.31 ± 0.03 0.34 ± 0.04 0.35 ± 0.03 
Spleen (g%) 0.19 ± 0.02 0.22 ± 0.02 0.22 ± 0.03 0.22 ± 0.01 0.19 ± 0.02 
 
 
 
Table 7.5. Hematological and clinical chemistry data for Wistar rats after 12 weeks s.c. 
implantation of PCL and PCL-O discs (Means ± SD are shown, n=3, except*; n=2). 
 
WBC: total white blood cell count, RBC: red blood cell count, HGB: hemoglobin, HCT: hematocrit, MCV: 
mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin 
concentration, PLT: Platelet count, Diff: white blood cell differential count, K: potassium, Na: sodium, Cl: 
chloride, ASAT: aspartate aminotransferase (U/l), ALAT: alanine aminotransferase, AFOS: alkaline 
phosphatase, γ-GT: gamma glutamyltransferase 
 
 PCL PCL-O:8-88 PCL-O:4-88 PCL-O:2-37 Control
WBC (109/l) 3.7 ± 1.0 3.7 ± 0.6 4.3 ± 1.2 4.1 ± 0.9 4.0 ± 1.0
RBC (1012/l) 7.5 ± 0.3 7.6 ± 0.4 7.9 ± 0.2 7.8 ± 0.5 7.6 ± 0.4
HGB (g/l) 139 ± 9 151 ± 7 153 ± 2 152 ± 10 152 ± 6
HCT (%) 42.5 ± 2.5 45.7 ± 3.2 46.1 ± 0.1 45.9 ± 2.8 45.6 ± 1.8
MCV (fl) 57 ± 3 60 ± 3 59 ± 1 58 ± 2 59 ± 2
MCH (pg) 18.7 ± 1.1 19.8 ± 0.2 19.4 ± 0.5 19.3 ± 0.6 19.6 ± 0.3
MCHC (g/l) 329 ± 4 330 ± 12 332 ± 3 331 ± 2 333 ± 2
PLT (109/l) 838 ± 95 717 ± 34 780 ± 80 777 ± 21 709 ± 26
  Diff   
Lymphocytes (%) 77.6 ± 0.8 80.1 ± 4.5 77.3 ± 4.6 81.2 ± 3.0 75.0 ± 3.5
Monocytes (%) 11.6 ± 0.5 10.0 ± 1.5 11.0 ± 2.0 9.7 ± 2.3 10.6 ± 1.4
Granulocytes (%) 10.9 ± 0.6 9.9 ± 4.5 11.6 ± 3.1 9.1 ± 1.0 14.4 ± 2.1
   
K (mmol/l) 6.1 ± 0.3 6.0 ± 0.5 6.0 ± 0.1 6.6 ± 0.2 6.1 ± 0.5
Na (mmol/l) 148 ± 2 147 ± 0 147 ± 1 147 ± 1 148 ± 1
Cl (mmol/l) 103 ± 1 103 ± 2 103 ± 1 103 ± 0 103 ± 1
Creatinine (µmol/l) 58 ± 7 59 ± 1 60 ± 4 59 ± 4 57 ± 5
ASAT (U/l) *131; 81 112 ± 60 81 ± 27 89 ± 24 76 ± 13
ALAT (U/l) 80 ± 37 78 ± 40 50 ± 7 60 ± 11 42 ± 4
AFOS (U/l) 115 ± 4 109 ± 8 105 ± 16 114 ± 17 122 ± 29
γ-GT (U/l) 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
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8 Three-Step Tumor Targeting of Paclitaxel Using 
Biotinylated PLA-PEG Nanoparticles and Avidin-Biotin 
Technology: Formulation Development and In Vitro 
Anticancer Activity 
 
 
 
Abstract. Despite recent advances in cancer therapy, many malignant tumors still lack 
effective treatment and the prognosis is very poor. Paclitaxel is a potential anticancer drug, 
but its use is limited by the facts that paclitaxel is a P-gp substrate and its aqueous solubility 
is poor. In this study, three-step tumor targeting of paclitaxel using biotinylated PLA-PEG 
nanoparticles and avidin-biotin technology was evaluated in vitro as a way of enhancing 
delivery of paclitaxel. Paclitaxel was incorporated both in biotinylated (BP) and non-
biotinylated (LP) PEG-PLA nanoparticles by the interfacial deposition method. Small (mean 
size ~110 nm), spherical and slightly negatively charged (-10 mV) BP and LP nanoparticles 
achieving over 90 % paclitaxel incorporation were obtained. The successful biotinylation of 
nanoparticles was confirmed in a novel streptavidin assay. BP nanoparticles were targeted 
in vitro to brain tumor (glioma) cells (BT4C) by three-step avidin-biotin technology using 
transferrin as the targeting ligand. The three-step targeting procedure increased the anti-
tumoral activity of paclitaxel when compared to the commercial paclitaxel formulation 
Taxol® and non-targeted BP and LP nanoparticles. These results indicate that the efficacy of 
paclitaxel against tumor cells can be increased by this three-step targeting method.   
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted from: Pulkkinen M, Pikkarainen J, Wirth T, Tarvainen T, Haapa-aho V, Korhonen H, 
Seppälä J, Järvinen K: Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG 
nanoparticles and avidin–biotin technology: Formulation development and in vitro anticancer 
activity. Eur J Pharm Biopharm 70: 66-74, 2008. © Elsevier Ltd. 2008 
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8.1 INTRODUCTION 
There are many cases where the administration of anticancer drugs is limited by their 
unsatisfactory properties such as poor solubility, narrow therapeutic window and P-
glycoprotein (P-gp) substrate specificity. For example, paclitaxel is a very promising 
chemotherapy agent but unfortunately it shows poor aqueous solubility. The currently 
available commercial formulation Taxol® contains Cremophor EL (polyethoxylated castor 
oil) and ethanol as excipients to promote solubilization. Cremophor EL can induce severe 
side-effects including hypersensitivity reactions, nephrotoxicity and neurotoxicity (Singla et 
al. 2002). In addition to the formulation problems, paclitaxel is a substrate for the P-gp 
transporter which impedes the permeability of the drug through physiological barriers and 
prevents it gaining access to tumor tissue (Rowinsky et al. 1989; Heimans et al. 1994; 
Sparreboom et al. 1997; Fellner et al. 2002).  
Paclitaxel targeting utilizing stealth nanoparticles made of hydrophobic polymers could 
solve some of the problems associated with paclitaxel delivery. No harmful excipients are 
needed to formulate paclitaxel preparations if nanoparticles prepared from hydrophobic 
polymers are used for the drug delivery. When compared to non-stealth nanoparticles, 
stealth nanoparticles show extended blood circulation times, resulting in a better tissue 
distribution (Olivier 2005). Tumor targeting of drug may be achieved either by a direct 
targeting method or by resorting to the pretargeting multistep method. In the case of direct 
targeting, the targeting ligand is attached onto the nanoparticles. Whereas in the case of the 
pretargeting method, the ligand, intended to be concentrated and localized in the tumor, is 
administered before the administration of drug loaded carrier. Typically the pretargeting 
method results in a longer circulation time of the nanoparticles after repeated dosing when 
compared to directly targeted nanoparticles (Harding et al. 1997). This can be explained by 
the fact that the pretargeting method does not unfavorably change the physicochemical 
properties of the nanoparticles since it is not necessary to attach a targeting ligand, such as 
a large antibody, onto the surface of the nanoparticles.  
The use of avidin-biotin technology may represent a versatile approach to target 
nanoparticles into the tumor tissue. The avidin-biotin bond is the strongest protein-ligand 
interaction known in nature (Green 1975). The avidin-biotin technology has long been 
utilized in immunohistochemistry and molecular biology (Goodwin and Meares 2001). 
Recently, this technology has been applied for drug targeting (De La Fuente et al. 1997; 
Hoya et al. 2001; Boerman et al. 2003; Nobs et al. 2006; Rodríguez et al. 2007). The three-step 
method using avidin-biotin technology that is used in human imaging and therapy of 
cancer tissue (Paganelli et al. 1998; Cremonesi et al. 1999; Breitz et al. 1999; Knox et al. 2000) 
consist of the following steps: (i) i.v. administration of biotinylated targeting ligands, (ii) i.v. 
administration of avidin and (iii) i.v. administration of biotinylated drug or drug-loaded 
carrier.  
The aim of this study was to develop paclitaxel loaded stealth nanoparticles which could 
be targeted into the cancer cells via three-step avidin-biotin technology. To achieve this 
goal, PLA-PEG-Biotin polymer was synthesized and characterized. Biotinylated paclitaxel-
loaded nanoparticles were prepared by the interfacial deposition method. The resulting 
formulations were characterized in terms of size, charge, morphology, drug encapsulation 
and drug release. Furthermore, the functionality of biotinylated nanoparticles was assessed 
by a newly-developed biotin-avidin affinity assay. The in vitro cytotoxicity of the 
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nanoparticles was evaluated against glioma cells (BT4C) using biotinylated transferrin as a 
targeting ligand.  
8.2 MATERIALS AND METHODS 
8.2.1 Materials 
Paclitaxel (from Taxus yannanensis) (T-1912) was obtained from Sigma-Aldrich Co. Ltd. (St 
Louis, USA). Taxol® was supplied by Bristol-Myers Squibb (New York, USA). D,L-Lactide 
was purchased from Purac (Gorinchem, Netherlands). Me-PEG-OH (~2000 g/mol) was 
obtained from Fluka (Seelze, Germany). HO-PEG-NH2 was purchased from Nektar 
Therapeutics (Mw=3400 g/mol, Huntsville, AL, USA). NHS-biotin, triethylamine, stannous 
octoate, Dulbecco’s Modified Eagle’s Medium and Eagles's minimum essential medium 
were products of Sigma-Aldrich Co. Ltd (St Louis, USA). L-glutamine, nonessential amino 
acids and sodium pyruvate were provided by Gibco (Grand Island, NY, USA). Biotinylated 
transferrin (A-2666), neutravidin and 1% glutamax were products of Molecular Probes 
(Leiden, Netherlands) while fetal bovine serum was from HyClone (Logan, Utah, USA). 
CellTiter-Blue™ reagent was obtained from Promega (Southampton, UK). Sterile water and 
NaCl 0.9% were obtained from Baxter (Vantaa, Finland) and deionized water was 
processed in a Milli-Q system (Millipore). Other reagents were of reagent grade. 
8.2.2 Polymer synthesis and characterization 
8.2.2.1 PLA-PEG-Biotin synthesis by solution polymerization 
Polymer synthesis was performed using the method of Salem et al. (2001) with slight 
modifications. Briefly, Biotin-PEG-OH was prepared as follows. 1 g of HO-PEG-NH2 
(Mw:3400 g/mol) was dissolved in 2 ml of acetonitrile at room temperature. Triethylamine 
(80 µl) and dichloromethane (1 ml) were added and mixture was stirred for 1 min. Next, 
NHS-biotin (0.25 g) was added and stirring was continued overnight under argon. The 
mixture was filtered and the biotin-PEG-OH –polymer was precipitated with an excess of 
diethyl ether. The precipitated polymer was filtered and purified by dissolving it into hot 2-
propanol (70 °C) and then allowed to cool down. The reprecipitated polymer was then 
filtered again. Water residues were removed by dissolving the polymer in toluene and 
refluxing for 4 h with a Dean-Stark trap. The toluene was evaporated and the polymer was 
dried in a vacuum. 
Purified Biotin-PEG-OH (0.3 g) and D,L-lactide (1.8 g) were dissolved in 10 ml of toluene 
and mixture heated to 70°C. Stannous octoate solution in toluene (0.03 mol-% in relation to 
D,L-lactide) was added and the reaction was carried out by refluxing at 111°C for 4.5 h 
under argon. After the reaction, toluene was removed with vacuum distillation and the 
reaction was completed under argon flow for 1 h at 140°C. The product was purified by 
precipitating the polymer from dichloromethane solution (10 ml) by adding it to an excess 
of cool diethyl ether. The PLA-PEG-Biotin polymer was dried and stored in a vacuum. The 
reaction steps were followed by 1H-NMR analysis which confirmed that the products 
contained the desired structures. 
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8.2.2.2 PLA-PEG synthesis by melt polymerization 
PLA-PEG was prepared by melt polymerization using stannous octoate (0.03 mol%) as an 
initiator and Me-PEG-OH as a co-initiator. A round-bottom flask was charged with D,L –
lactide (25.9 g) and Me-PEG-OH (2.5 g). Polymerization was carried out at 140 °C with 
magnetic stirring under argon for 16 h. After polymerization, the product was purified by 
precipitating the polymer/dichloromethane solution with an excess of hexane, and dried in 
a vacuum. 
8.2.3 Polymer characterization 
Molecular weights (Mw, Mn) were determined by size exclusion chromatography (SEC) 
(Waters System Interface module, Waters 510 HPLC Pump, Waters 410 Differential 
Refractometer, Waters 717plus autosampler, and four linear PL gel columns: 104, 105, 103 
and 100 Å connected in series) The flow rate of the chloroform was 1 ml/min and the 
injection volume was 200 µl. Before analysis, the samples were filtered through a 0.5 µm 
Millex SR filter. Monodisperse polystyrene standards were used for the calibration. 
More accurate structures of the prepared polymers were provided by 1H NMR. For 1H 
NMR measurements, the samples were dissolved in DMSO-d6 in 5-mm NMR tubes at 
room temperature. The sample concentration was about 1.0 % by weight. NMR spectra 
were recorded on a Varian Gemini 2000 spectrometer working at 300 MHz for protons.  
Melting temperatures (Tm) and glass transition temperatures (Tg) were measured by 
differential scanning calorimetry (DSC) (Mettler Toledo Star) in a nitrogen environment. 
Samples (5-10 mg) were heated twice, at a rate of 10°C/min, to ensure that their thermal 
histories were similar. The temperature range was between -100°C and 250°C. The melting 
temperature and glass transition temperature were determined from the second heating 
scan.  
8.2.4 Preparation of nanoparticles 
Nanoparticles were prepared by the interfacial deposition solvent displacement method 
(Fessi et al. 1989). Briefly, 1 mg of PLA-PEG-Biotin and 99 mg of PLA-PEG (BP) or 100 mg 
of PLA-PEG (LP) were dissolved in 1 ml of acetone containing 1 mg of paclitaxel. The 
mixture was vortexed until solids dissolved and then 9 ml of acetone was added into the 
solution just before adding the organic phase drop-wise into 10ml of water phase (4 ml 
NaCl 0,9 % and 6 ml H2O) with magnetic stirring. The suspension was allowed to stabilize 
with stirring for 5 min. Acetone and the surplus of water were removed by rotavapor 
(BÜCHI, Flawil, Switzerland) at 25°C under nitrogen flow. The suspension was kept at 200 
mbar for 2 h to remove all of the acetone from the solution. The suspension was made up to 
a volume of 4 ml with water and sonicated for 2 min (Finnsonic m03, Lahti, Finland) to 
brake cluster of particles. Finally, the suspension was filtered through a 1.2 µm membrane 
filter to remove aggregates and non-incorporated drug. Unloaded nanoparticles were 
prepared using the same procedure without the drug. For cell studies, all steps were 
completed aseptically with sterilized equipment.  
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8.2.5 Physicochemical characterization of nanoparticles 
8.2.5.1 Determination of drug amount 
The amount of paclitaxel in nanoparticles was determined using the previously described 
extraction method with slight modifications (Wang et al. 1996). The paclitaxel content was 
determined both from the nanoparticle suspension and from washed lyophilized 
nanoparticles. In the case of the suspension method, 100 µl of aqueous nanoparticle 
suspension was dried under a nitrogen stream and the drug content in the dried 
nanoparticles was determined as described below. The washed lyophilized nanoparticles 
were prepared as follows: 0.5 ml of nanoparticle aqueous suspension was centrifuged 
(Heraeus Biofuge 17 RS, Heraeus Sepatech, Hanau, Germany) at 17000 rpm for 30 min 
(+20°C). Then the sample was washed with 1 ml of Mq-water and centrifuged again. The 
resulting pellet was frozen (-86°C) and dried with freeze dryer for 24 h (FST Systems Inc., 
New York, USA). Either the exactly weighed nitrogen stream dried nanoparticles (~2.5 mg) 
or the lyophilized nanoparticles (~2.5 mg) were dissolved in 1 ml of DCM and then 5 ml of 
acetonitrile-water (50:50) solution was added and mixture was vortexed vigorously for 2 
min. A nitrogen stream was introduced until the polymer precipitated and a clear solution 
was obtained. The solutions with precipitated polymer were centrifuged for 10 minutes at 
5000 rpm (Megafuge 1.0R, Heraeus instruments, Hanau, Germany) and the supernatant 
was collected. This was followed by a wash with 5 ml of acetonitrile-water (50:50) and 
centrifugation at 5000 rpm for 10 min. The supernatant was collected and the samples were 
made up to volume with acetonitrile-water (50:50), and the paclitaxel concentration was 
analyzed by HPLC as described below. The extraction efficiency of paclitaxel was 
determined as follows: equal concentrations of paclitaxel and polymer when compared to 
their concentration in the nanoparticles were dissolved in 1 ml of DCM and extraction was 
performed as described above. The extraction efficiency of paclitaxel was 95.6% (n=5, 
SD=2.6) and this value was used to calculate the amount of drug in the particles.   
The Gilson HPLC system consisted of a detector (UV/VIS-151), pump (321), autoinjector 
(234), interface (Hercule Lite for Borwin 1.5) and integrator (Borwin 1.5). The mobile phase 
consisted of a mixture of acetonitrile and water (50:50 v/v). A reverse-phase Supelcosil®  C-
18 column (150 x 4.6mm id, pore size 5 µm, Supelco, Bellefonte, USA) was used for the 
chromatographic separation with an injection volume of 20 µl. Paclitaxel was detected at 
227 nm and the area under the curve was used for quantification. The calibration curve of 
the paclitaxel was linear over the range 0.05-50 µg/ml with a correlation coefficient of 
R2≥0.999).  
 
The encapsulation efficiencies of the drug loading were calculated using Equation 2 and 3, 
respectively.   
Encapsulation efficiency (%) 
(paclitaxel amount in nanoparticles(mg)/initial drug amount(mg)) X 100%                    (Eq. 2) 
Drug loading (%) 
(paclitaxel amount in nanoparticles(mg)/dry weight of nanoparticles(mg)) X 100%      (Eq. 3) 
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8.2.5.2 In vitro drug release  
The in vitro release of paclitaxel from nanoparticles was determined by the 
ultracentrifugation method. A total of 40 µl of nanoparticle aqueous suspension was added 
into 5 ml of pH 7.4 phosphate-buffered saline solution containing 0.2 % of 
sodiumlaurylsulfate (SLS). SLS was added into the release medium to enhance the 
solubility of paclitaxel. The nanoparticle sample contained about 10 µg of paclitaxel in the 
release studies. The solubility of paclitaxel in the release medium was analyzed to be 38 
µg/ml, and thus the release studies were conducted under sink conditions (maximum 
paclitaxel concentration in release medium was 2 µg/ml). Nanoparticles were incubated in 
10 ml tubes at a frequency of 120 strokes/min at 37°C (Grant OLS200, Cambridge, UK). 
Samples were withdrawn at predetermined time points and nanoparticles were separated 
by high speed centrifugation at 25000 rpm for 30 min at 4°C in a Beckman Avanti J-30I 
centrifuge (rotor JA-25.15, 74200 G). The concentration of paclitaxel in the supernatant was 
determined by the HPLC as described in 8.2.5.1.  
8.2.5.3 Particle size distribution, morphology and zeta-potential of nanoparticles  
Particle mean size and size distribution were measured by the light scattering method 
using Nicomp Zeta Potential/Particle Sizer (model 380 XLS, NicompTM, Santa Barbara, 
CA). The nanoparticle suspension was diluted in purified water before the measurement. 
The zeta potential of the nanoparticles was measured by the Malvern Zetasizer 3000HS 
(Malvern Instruments, UK), and the suspension samples were diluted in 20 mM Hepes (pH 
7.4). For each sample, the mean value of at least 10 measurements was calculated. 
The morphology of the nanoparticles was studied by transmission electron microscopy 
(TEM) (JEM-1200EX, JEOL Ltd., Tokyo, Japan). A drop of nanoparticle suspension diluted 
in water was placed on a carbon-coated copper grid. After 1 min, the sample was washed 
with ultra-purified water and the excess of fluid was removed by a piece of filter paper. 
Finally, the sample was negative stained with 2% phosphotungstic acid solution for 30 s. 
and the excess of the fluid removed and the dry sample analysed.  
8.2.5.4 Biotin-affinity assay 
The accessibility and functionality of biotin on the surface of nanoparticles were evaluated 
by the biotin-streptavidin binding method. Nanoparticles with (BP) and without (LP) biotin 
were diluted in filtered (0.45 µm) binding buffer (20 mM sodium phosphate, 0.15 M NaCl, 
pH 7.5). A HiTrapTM Streptavidin HP column (Amersham Biosciences, Uppsala, Sweden) 
was equilibrated with the binding buffer according to product instructions. The samples 
were pumped into the column by peristaltic pump at a flow rate of 0.1 ml/min. The fraction 
of outcoming (i.e. not bound) nanoparticles was measured by two techniques: an HPLC-
GPC method and a light scattering method (NICOMP). The light scattering method was 
based on the intensity value which is proportional to the amount of particles. HPLC system, 
described in 8.2.5.1, was used with a size exclusion column (PL aquagel-OH Mixed 8 µm, 
300 x 7.5 mm, Polymer Labs, UK) and 100 µl injection volume. The HPLC measurement 
was performed at 225 nm with a flow rate of 0.4 ml/min using binding buffer as a mobile 
phase. Standard curves were made by diluting the nanoparticle suspension in binding 
buffer. 
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8.2.6  In vitro anti-tumoral activity  
BT4C cells, rat glioma cell line, were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10 % fetal bovine serum and 1% glutamax. HepG2 cells, Human 
hepatocellular liver carcinoma cell line, were grown in Eagle's minimum essential medium 
adjusted to contain 1.5 g/L sodium bicarbonate and supplemented with 2 mM L-glutamine, 
0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 10% FBS, penicillin (100 IU/ml) 
and streptomycin (100 µg/ml). Cells were grown in an atmosphere of 95 % humidified air 
and 5 % CO2 at 37°C. Exponential growth was maintained using appropriate splitting and 
renewal of medium. For the experiments, cells were seeded onto 96-well plates (Cellstar) at 
a density of 10000 cells/well and incubated overnight.  
The effects of studied formulations at paclitaxel concentrations from 0.1 to 50 µg/ml on 
cell viability were studied in the presence and absence of targeting. The three-step method 
was used for the targeting of paclitaxel loaded biotinylated nanoparticles (BP), i.e. (1) cells 
were incubated with biotinylated transferrin (50 µg/ml) for 15 min, (2) cells were incubated 
with neutravidin (50 µg/ml) for 5 min and (3) cells were incubated with BP nanoparticles 
for 15 min. The one step method was used for the non-targeted paclitaxel loaded 
biotinylated (BP) and non-biotionylated (LP) nanoparticles and for Taxol®, i.e. cells were 
incubated with BP or LP nanoparticles or Taxol for 15 min. After every step, the wells were 
washed with 200 µl of PBS (pH 7.4). Then, cells were incubated with culture medium 
(200µl/well) for 3 days. In every case, the BP, LP and Taxol® samples were diluted in culture 
medium and administered to the cells in a volume of 100 µl/well. 
After 3 days’ growth, 100 µl of fresh culture medium was changed to the cells and cell 
viability was assessed by adding 20 µl of CellTiter-blue reagent. The assay is based on the 
reductive ability of living cells to metabolize resazurin into a fluorescent end product 
resorufin. After 2 h incubation, the measurements were conducted fluorometrically by a 
Victor multiplate system (excitation 544 nm and emission 590 nm, Perkin–Elmer, HTS 7000 
Plus, Bio Assay Reader / Victor2 1420 multilabel counter, Perkin Elmer, Turku, Finland). 
Cell viability was calculated by Equation 4:  
Cell viability %= (Fluorescence test cells / Fluorescence control cells) X 100                     (Eq. 4) 
 
where Fluorescence control cells is the fluorescence of control cells incubated with cell culture 
media only.  
 
8.2.7 Statistical analysis 
A non-parametric Kruskal–Wallis test was used to test the statistical significance of 
differences between groups. Significance in the differences of the means was tested using 
the Mann-Whitney test. The level of significance was taken as P<0.05. 
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8.3 RESULTS  
8.3.1 Polymerization  
The biotinylated and pegylated polylactides were successfully polymerized using solution 
polymerization and melt polymerization, respectively. More specific details of the polymers 
are given in Table 8.1. The attachment of biotin was confirmed by 1H-NMR (Figure 8.1) and 
DSC measurements. Two urea protons from the cyclic biotin can be seen in the Biotin-NHS 
(data not shown), Biotin-PEG-OH and PLA-PEG-Biotin spectra at 6.33 and 6.40 ppm. Due 
to the low concentration of biotin, the signal is very low in PLA-PEG-Biotin spectrum. The 
covalent bond between Biotin-NHS and HO-PEG-NH2 was confirmed from the free amide 
proton signal at 7.81 ppm (NHCO). Melting temperatures for Biotin-NHS and HO-PEG-
NH2 were 216°C and 61°C, respectively. Furthermore, DSC revealed only one peak for 
Biotin-PEG-OH at 54°C also confirming that no free biotin was present.  
8.3.2 Characterization of nanoparticles 
Nanoparticles were successfully prepared by the interfacial deposition solvent 
displacement method using as the polymer either PLA-PEG (LP) or mixtures of PLA-PEG 
and PLA-PEG-Biotin (BP). Paclitaxel was encapsulated effectively both within the LP and 
BP nanoparticles as > 90 % incorporation was obtained in both cases (Table 8.2). The 
encapsulation efficiency of washed lyophilized nanoparticles was close to that achieved 
with direct measurement from the nanoparticle suspension. This confirmed that the drug 
had been effectively incorporated into the nanoparticles. The size of both LP and BP 
nanoparticles was close to 100 nm with a fairly narrow size distribution (Table 8.2). As an 
example, the TEM picture reveals the spherical shape and homogenous size distribution of 
the BP nanoparticles (Figure 8.2.). Both LP and BP nanoparticles exhibited a negative 
surface charge with zeta-potential values close to -10 mV. It can be concluded that 
biotinylation of nanoparticles did not substantially change the characteristics of the 
nanoparticles when compared to LP nanoparticles.  
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Figure 8.1. 1H NMR spectra of synthesized PEG-biotin-OH (A) and PLA-PEG-biotin (B) in DMSO-
d6. Characteristic peaks of biotin are shown in the closeup detail for PLA-PEG-biotin.*DMSO 
peak, **H2O peak. 
 
 
Table 8.1. Molecular weights (Mw,Mn), glass transition temperatures (Tg), melting temperatures 
(Tm) and polydispersities (Mw/Mn) of studied polymers. 
 
Polymer PEG-chain 
(g/mol) 
Mw
(g/mol) 
Mn
(g/mol) 
Mw/Mn Tg (˚C) Tm (˚C)
PLA-PEG 2000 40500 20000 2.0 35 - 
PLA-PEG-Biotin 3400 22600 19900 1.1 15 - 
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Figure 8.2. TEM photograph of biotinylated nanoparticles (BP). Scale bar 200 nm 
(magnification 50,000x). 
 
 
 
Table 8.2. Size, encapsulation efficiency and zeta potential of paclitaxel loaded (1 % w/w) non-
biotinylated (LP) and biotinylated (BP) nanoparticles. Encapsulation efficiency was determined 
by two methods as described in 8.2.5.1.  Data are presented as the mean ± SD (n= 3-4, 
except: *n=5).   
 
The encapsulation efficiency was measured from washed lyophilized nanoparticles (W ) and with direct 
measurement from the nanoparticle suspension (S). 
 
 
8.3.3 Biotin-Affinity assay 
The presence of functional biotin on the surface of the nanoparticles was confirmed by the 
developed biotin-affinity assay, i.e.  nanoparticles were pumped through the Streptavidin-
column and the fraction of unbound nanoparticles was determined.  Biotin molecules bind 
to avidin and therefore biotinylated nanoparticles (BP) are retained inside the column 
whereas nanoparticles without functional biotin (LP) are not retained. Both HPLC-GPC and 
light scattering (NICOMP) methods confirmed that the biotinylated nanoparticles had been 
effectively bound into the Streptavidin column whereas non-biotinylated nanoparticles 
were not bound (Figure 8.3). 
 
Nanoparticles Size (nm) Encapsulation      
efficiency (%)W  
Encapsulation  
efficiency (%)S 
Zeta-potential   
(mV)   
 
LP  104,9 ± 38,6* 92,9 ± 3,1 93,5 ± 5,2 -10,4 ± 0,5 
BP 106,8 ± 38,5 93,7 ± 5,0 92,4 ± 3,9 -10,2 ± 0,5
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Figure 8.3. Binding of biotinylated (BP) and non-biotinylated (LP) nanoparticles in the 
streptavidin column (n = 3, ± SD are shown). Measurements were made by NICOMP light 
scattering and HPLC-SEC methods. 
 
8.3.4 In vitro release study 
The in vitro release of paclitaxel from biotinylated nanoparticles is shown in Figure 8.4. The 
release profile shows a high burst release during the first hour followed by a slower drug 
release. Virtually all of the paclitaxel was released during 24 hours. The biotinylation of 
nanoparticles did not change the release profile of paclitaxel since the profiles were 
identical for BP (Figure 8.4) and LP nanoparticles (data not shown in Figure 8.4 for the sake 
of clarity).  
       
 Figure 8.4. In vitro release rate of paclitaxel from biotinylated nanoparticles (BP) in PBS (pH 
7.4) with 0.2% SLS at 37°C (mean ± SD, n = 4). 
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8.3.5 In vitro anti-tumoral activity 
The effects of Taxol®, paclitaxel loaded LP nanoparticles and paclitaxel loaded non-targeted 
and targeted BP nanoparticles were studied on glioma (BT4C) and hepatic (HepG2) cell 
viability. Paclitaxel was evaluated in the concentration range of 0.1 to 50 µg/ml (equivalent 
to BP and LP nanoparticle concentrations up to 5 mg/ml). In the case of each formulation, 
cell viability decreased with an increase in the paclitaxel concentration (Figure 8.5). 
Incubation of cells with unloaded LP or BP nanoparticles or neutravidin or biotinylated 
transferrin did not evoke any cytotoxicity since the cell viability value remained > 90 % 
(data not shown). 
When compared to Taxol®, paclitaxel loaded non-targeted LP or BP nanoparticles were 
not more effective against brain tumor cells at the tested concentrations (Figure 8.5). When 
the effects of the formulations on control cell viability (HepG2) were studied, the three step 
targeting procedure did not increase the anti-tumoral activity of paclitaxel when compared 
to non-targeted BP nanoparticles (data not shown). Instead, the three-step targeting 
procedure using BP nanoparticles increased significantly the cytotoxicity of paclitaxel at 
concentrations of 10 and 50 µg/ml when compared to Taxol® and non-targeted BP and LP 
nanoparticles. However, the potency of this targeted formulation decreased when more 
diluted samples were used.   
 
 
Figure 8.5. Viability of glioma cells (BT4C) after incubation with Taxol, nanoparticles (LP), 
biotinylated nanoparticles (BP) and biotinylated nanoparticles with the three-step targeting 
using biotinylated transferring (T) and neutravidin (av). Data are presented as means ± SEM (n 
= 15–16). *, ** and *** statistically different from the value of targeted nanoparticles (T + av 
+ BP) (*P < 0.05, **P < 0.01, ***P < 0.001 by Kruskal–Wallis, Mann–Whitney’s U-test). 
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8.4 DISCUSSION 
Paclitaxel is a potent anticancer drug which use is restricted by its poor aqueous solubility 
and by the fact that paclitaxel is a P-gp substrate. The poor aqueous solubility requires the 
inclusion of a harmful excipient, Cremophor EL, in Taxol®. The commercial non-targeted 
paclitaxel nanoparticulate formulation Abraxane®, based on albumin, does not contain 
Cremophor EL. It can be postulated that targeted nanoparticles made of hydrophobic 
materials could further enhance the potency of paclitaxel therapy.  
In the present study, a rapid and reproducible preparation method was developed which 
resulted in the production of spherical paclitaxel loaded biotinylated and non-biotinylated 
nanoparticles with a narrow particle size distribution (size about 100 nm) and a slightly 
negative surface charge. The negative surface charge of the particles may be attributable to 
the carboxylic groups of polylactic acid. The present zeta-potential value of LP 
nanoparticles (-10 mV) is in agreement with earlier studies where zeta-potential values for 
pegylated or polyvinyl alcohol covered PLA based nanoparticles have been reported (Riley 
et al. 1999; Dong and Feng 2004; Mo and Lim 2005). Interestingly, biotinylation did not 
markedly change the surface charge of nanoparticles, though biotin is known to possess a 
positive charge. The paclitaxel release from the nanoparticles was rapid and virtually all of 
drug was released within 24 hours (Figure 8.4). The fast release of the drug is probably 
caused by the large surface area of the nanoparticles and the short diffusional distance. It 
has also been reported earlier that paclitaxel release from PLA based nanoparticles is rapid 
in vitro (Fonseca et al. 2002). It can be concluded that the present nanoparticles should be 
well suited for i.v. dosing in terms of their physicochemical properties since it is known 
that long-lasting circulating injected nanoparticles should be small, slightly negatively 
charged and covered with a protective PEG layer (Olivier 2005).  
Avidin has four binding sites for biotin molecules, and the binding sites are close to each 
other which leads to steric hindrance (Goodwin and Meares 2001). In the case of 
biotinylated stealth nanoparticles, also the dense PEG layer on the nanoparticle surface can 
cause steric hindrance, resulting in a decrease in the activity of biotin. Therefore, the 
biotinylated conjugates should be separated by spacers in order to achieve optimal biotin-
avidin binding. In the present study, the biotin-PEG-PLA possessed a longer PEG chain 
(3400 g/mol) than PEG-PLA (2000 g/mol). It was confirmed that BP nanoparticles resulted 
in binding of biotin to avidin (Figure 8.3).  
A glioma cell line (BT4C) was used to evaluate the anti-tumoral activity of paclitaxel 
loaded nanoparticles and Taxol®. Brain tumors are a serious form of cancer as the prognosis 
of patients with primary tumors or brain metastases is very poor since there are few 
effective treatments against this aggressive disease (Kornblith and Walker 1988; De Angelis 
2001; Cohen et al. 2004). For example, the prognosis of the fairly common malignant 
primary brain tumors such as glioma, is very unsatisfactory with less than one year 
medium survival (Scott et al 1998). Usually, brain tumors are treated by brain irradiation or 
surgery (van den Bent 2003; Sathornsumetee et al. 2007). The use of chemotherapy is less 
common because of the poor abilities of most chemotherapy agents to cross the blood brain 
barrier (BBB) due to tight endothelium and P-gp activity. Targeted nanoparticles may 
enhance paclitaxel delivery to the brain tumor after i.v. administration because 
nanoparticles are known to be able to penetrate through the BBB (Gulyaev et al. 1999; 
Lockman et al. 2003; Koziara et al. 2004; Steiniger et al. 2004). The BBB is probably more 
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leaky in the region of the tumor than in normal brain due to enhanced vasculature which 
will increase the permeation of nanoparticles to these sites (Steward 1994; van den Bent 
2003). Furthermore, paclitaxel has a radiosensitizing ability against glioma which makes it 
an interesting candidate for treatment of brain tumors since these malignancies are usually 
treated by radiotherapy (Tishler et al. 1992). 
In the present study, transferrin was selected as a targeting ligand because transferrin 
receptors are highly expressed on tumor cells and the brain capillary endothelium (Wagner 
et al. 1994; Huwyler et al. 1996). Transferrin is an iron-transporting serum glycoprotein 
which is efficiently taken up into cells by receptor-mediated endocytosis. Previously, 
transferrin has been successfully used to target various molecules and liposomes into tumor 
and brain tissue (Huwyler et al. 1996; Ishida et al. 2001; Shi et al. 2001; Maruyamaa et al. 
2004; Gijsens et al. 2002). The present result indicate that the three-step targeting procedure 
increases markedly anti-tumoral activity of paclitaxel when compared to the commercial 
paclitaxel formulation Taxol® and non-targeted biotinylated (BP) and non-biotinylated 
nanoparticles (LP) (at paclitaxel concentrations of 10 and 50 µg/ml). Moreover, without the 
targeting steps, drug loaded LP and BP nanoparticles did not show substantially different 
cytotoxicities against BT4C cells. An earlier study also indicated that biotinylation of 
nanoparticles did not enhance the cellular uptake of the non-targeted nanoparticles (Gref et 
al. 2003).  
8.5 CONCLUSIONS 
Paclitaxel loaded biotinylated PLA-PEG nanoparticles were successfully prepared. The 
produced nanoparticles displayed a high drug encapsulation efficiency and active 
functional biotin on their surface. The three-step targeting procedure using biotionylated 
nanoparticles increased markedly anti-tumoral activity of paclitaxel at concentrations of 10 
and 50 µg/ml when compared to Taxol® or the non-targeted nanoparticles. These results 
suggest that the efficacy of paclitaxel against tumor cells may be increased by the three-step 
targeting method.  
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9 General Discussion and Future Prospects 
Since life expectancy continues to increase, diseases which occur predominantly in the 
elderly (e.g. organ failures, cancers and bone fractures) will become more common and 
diminish the quality of life. Therefore, there is a great need for new biomaterials, based on 
more specific and efficient technologies, which would cure, prevent or relieve these serious, 
life-threatening diseases. During recent decades, knowledge about the properties of 
biomaterials has increased tremendously and these materials can be tailored for different 
purposes.  
In the present work, novel ε-caprolactone based poly(ester-amide)s that are enzyme 
sensitive polymers undergoing surface erosion were developed for pharmaceutical 
applications. These polymers can overcome some of the major problems related to the 
unmodified PCL, such as slow hydrolytic bulk erosion. In summary, in vitro PCL-O 
polymers eroded more quickly than PCL and the erosion rate of PCL-O was controlled by 
the PCL block length. Lipase was believed to be mainly responsible for enzymatic 
degradation of the PCL-O polymers. Proof-of-concept studies in rats confirmed that the 
erosion rate of PCL-O polymers was faster than that of PCL and the erosion rate of PCL-O 
can be controlled by the PCL block length. However, the in vivo erosion rate of PCL-O 
polymer was lower than the in vitro erosion rate in the presence of lipase. The reasons for 
this may be attributable to the reduced enzymatic activity and the lower availability of 
water in the in vivo situation. In addition, the different preparation method may have 
influenced the erosion rate as in vitro films were made by polymer casting and in vivo discs 
were meltpressed. 
PCL has been reported to be a biocompatible and safe biodegradable polymer. However, 
new modified polymers have to be carefully tested in terms of biocompatibility. In this 
study degradation, erosion and toxicity of PCL-O were evaluated in a rat model. The in vivo 
evaluation based on results from hematology, clinical chemistry and histology of the 
implantation area and main organs demonstrated that PCL-O polymers are biocompatible 
and safe biomaterials. However, it should be borne in mind that enzymatic activities and 
biocompatibility can vary between tissues and species. Therefore human clinical trials will 
be needed to confirm the degradation, functionality and safety of PCL-O based systems.  
An HPLC-MSn method was developed in order to monitor in detail the PCL-O 
degradation products. The method was proven to be useful in polymer degradation 
studies. It was possible to acquire more specific knowledge of the individual degradation 
products and this data can be hidden from other methods. For example, two consecutive 
oxazoline links were found in the polymer structure which could not be detected by NMR. 
Moreover, the results from HPLC-MSn revealed that pancreatic enzymes cleaved mainly 
ester bonds of PCL-O leaving the amide bonds intact. Recently, HPLC-MS methods have 
become increasingly used and this trend will probably continue due to ease of sample 
preparation and high separation efficacy of MS systems. 
Taken together, these results demonstrate that the studied -caprolactone based 
poly(ester-amide)s are enzyme sensitive polymers and that the erosion rate can be 
controlled by the PCL block length. This property would make PCL-O an interesting 
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candidate for various biomedical and pharmaceutical applications. For instance, lipase-
induced zero-order drug release from PCL-O polymers should be possible. In addition, 
PCL-O contains oxazoline groups which may be utilized in gene delivery. Functionalized 
cationic aliphatic polyesters based on caprolactone have been comparable with transfection 
efficiency and cytotoxicity with widely used transfection polymer polyethyleneimine 
(Vroman et al. 2007). PCL-O surface erosion due to enzymatic activity could also serve new 
possibilities in tissue engineering applications which have been recently tested with other 
aliphatic polyesters (Table 9.1).  
 
    
Table 9.1. Examples of recent advances of aliphatic polyester based materials in biomedical 
applications  
ELDI: ethyl-lysine diisocyanate; HA: hydroxyapatite; PCL: poly(ε-caprolactone); PE: pentaerythritol; 
PLGA: poly(lactic acid-co-glycolic acid); PNGEG/PhPh: polyphosphazene poly[(glycine ethyl 
glycinato)1(phenyl phenoxy)1phosphazene];  PPX-NH2: Poly(4-amino-p-xylylene)-co-(p-xylylene); RGD: 
Arginine-Glycine-Aspartate; TCP: beta-tricalcium phosphate; TGF-β1: transforming growth factor beta1. 
 
 
The treatment of cancer typically involves combinations of drugs, surgery and radiation. 
Despite recent advances in cancer therapy, many malignant tumors still lack effective 
treatment. Brain tumors are a serious form of cancer as the prognosis of patients with 
primary tumors or brain metastases is dismal since there are few effective treatments 
Proposed application Polymer  Reference 
 
Gene delivery  
 
PCL+PPX-NH2+biotin, matrix for adenovirus 
binding 
 
Hu et al. 2009 
 
 copolymers of ε-caprolactone and γ-bromo-
ε-caprolactone quarternized by pyridine  
Vroman et al. 2007 
Tissue engineering   
Bone substitute and scaffolds PCL/HA nanocomposites, scaffold Wie and Ma 2004; 
Rezwan et al. 2006 
 PLGA/PE/ELDI, injectable in situ forming 
graft  
Adhikari et al. 2008 
 Polyphosphazene–polyester blends 
(PNGEG/PhPh/PLGA) 
Deng et al. 2010 
 PCL film/scaffold + RGD peptide on surface Zhang et al. 2009 
 PCL-TCP  Abbah et al. 2009 
 
Cartilage repairment PCL implant with TGF-β1-loaded fibrin glue Huang et al. 2002 
 
Achilles tendon reconstruction PCL films Kazimoglu et al. 2003 
 
Cardiovascular tissue scaffold PCL/collagen nanofibre matrix Park et al. 2008 
 NaOH-treated PCL films Serrano et al. 2009 
 polyurethane/PCL shape memory stent Ajili et al. 2009 
 
Liver tissue scaffold  PCL scaffold Huang et al. 2007 
 
Tooth root canal filling material PCL + bioactive glass + bismuth oxycholide 
+ barium sulfate (Resilon®/Epiphany 
System) 
Miner et al. 2006 
 
Skeletal muscle tissue 
substitute  
PCL/Collagen nanofibres Choi et al. 2008 
 
Skin substitutes  PCL/collagen composites, membrane Dai et al. 2004 
 
Other substitute injectable polyurethane acrylates (based on 
poly(propylene glycol) or poly(caprolactone 
diol) and hydroxyethyl methacrylate 
 
Pereira et al. 2010 
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against this aggressive disease. For example, the prognosis of the fairly common malignant 
primary brain tumors such as glioma, is very unsatisfactory, with less than one year 
medium survival (Sathornsumetee et al. 2007). 
Recently, nanoparticles have been a subject of extensive research but only a few products 
have reached the market. An albumin based nanoparticulate formulation (Abraxane®) for 
i.v. delivery of paclitaxel was marketed a few years ago for the treatment of metastatic 
breast cancer (Gradishar 2005). The advantages of this 130 nm sized nanoparticle 
formulation have been mainly connected to avoidance of Chremophor EL and passive 
targeting of nanoparticles to large fenestrated cancer tissues. In addition, many polymeric 
nanoparticles and micelles have been tested in clinical trials (Wang et al. 2008a), but they 
have not established their position in the market. Targeted nanoparticles seem to be a 
promising strategy as they can gain access also to metastatic cancer cells after i.v. dosing. 
These particles can be programmed to find specified cells as well as to be effectively 
internalized by the cells which would improve the power of therapy and decrease side-
effects. Passive and active drug targeting using nanoparticles still faces challenges related 
to ineffective accumulation of nanoparticles within the target tissue due to their short 
circulation time and the accumulation of the particles in liver, spleen and lungs as well as 
problems associated with the physical and chemical stability of aqueous nanosuspension. 
The nanoparticles are typically formulated into an aqueous suspension due to the 
difficulties in their resuspension after the drying process (aggregates are easily formed). 
In the present study, paclitaxel loaded biotinylated PLA-PEG nanoparticles were 
successfully prepared. The produced nanoparticles displayed a high drug encapsulation 
efficiency and active functional biotin on their surface. The present result indicates that the 
three-step targeting procedure by biotin-avidin technology increases markedly the anti-
tumoral activity of paclitaxel when compared to the commercial paclitaxel formulation 
Taxol® and non-targeted nanoparticles. However, this effect was lost with low 
concentrations. This may be attributable to rapid drug release with low concentrations as 
the release rate was quite fast in sink conditions. In addition, transferrin seems to slightly 
increase cell growth which may diminish the power of the system at low drug 
concentrations. The tested avidin-biotin system was flexible as many different targeting 
ligands could be easily applied. Neutravidin (i.e. deglycosylated form of avidin) was 
applied in this system for diminishing the recognition process which can be more 
prominent with intact avidin. As high-throughput techniques for producing specific 
targeting moieties become available, one can predict that this technique may become a 
widely used since it can be modified easily for each cancer type. 
New polymeric materials have been extensively developed and tested in academia, but 
rarely have they reached the market. The reasons may be connected to long lasting and 
expensive biocompatibility testing. However, it can be postulated that a controlled and 
targeted drug delivery system will be more attractive way of extending patent times in the 
future as generic drug producers can quickly undercut prices of drugs once patents expire. 
This may increase the amount of new polymeric materials being introduced into novel 
formulations. The results of this thesis provide new information on aliphatic polyesters 
which could be used in pharmaceutical and biomedical applications, including controlled 
and targeted drug delivery.  
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10 Summary and Conclusions 
Polyesters are flexible pharmaceutical polymers as they can be formulated into various 
dosage forms. The present poly(ester-amide)s are an interesting way of modifying the 
polyesters as this combination produces polymers that exhibit enzyme enhanced 
degradation and erosion and this results in surface erosion with a tailored erosion rate 
whereas polyesters show bulk erosion.  Biotinylated polyester nanoparticles were produced 
to enhance the delivery of the anticancer drug paclitaxel. Three-step tumor targeting of 
paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology was 
evaluated in vitro. The following conclusions can be made from the present study. 
 
1. PCL-O polymers exhibited surface erosion in simulated intestinal fluid (SIF) and the 
erosion rate could be controlled by the PCL block length.  
 
2. A new direct and simple HPLC-ESI-MSn method was proven to be useful in the 
degradation product characterization and this revealed new information about the 
polymer structure. 
 
3. Lipase inhibitors paraoxon-ethyl and tetrahydrolipstatin inhibited enzymatic erosion 
of PCL-O in SIF and the results from HPLC-ESI-MSn showed that PCL-O was being 
cleaved mainly via the ester bonds. These results indicate that lipase was mainly 
responsible for the enzymatic degradation of PCL-O. 
 
4. Enzymatic surface erosion of PCL-O occurred after subcutaneous administration in 
rats, although the erosion rate was much lower in vivo than in vitro. 
 
5. Hematology, clinical chemistry and histological data did not reveal any marked 
toxicity attributable to the oxazoline linked polymers after 12 weeks of subcutaneous 
implantation in vivo in rats.  
 
6. Paclitaxel loaded biotinylated PLA-PEG nanoparticles were successfully prepared 
with appropriate physicochemical properties, including a high drug encapsulation 
efficiency, ~100nm size, slightly negative charge and active biotin on surface.  
 
7. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles 
and avidin-biotin technology increased the efficacy of paclitaxel substantially in vitro 
when compared to commercial Taxol® or the non-targeted nanoparticles.  
 
Taking together, these results suggest that PCL-O polymers are biocompatible and safe 
materials displaying enzyme sensitive surface erosion in vivo. Since the lipase enzyme is 
located in many tissues, it might be possible to utilize this enzyme sensitive degradation 
property of PCL-O to target a variety of physiological sites. Furthermore, biotinylated PLA-
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PEG nanoparticles are promising targeting formulations for drugs with narrow therapeutic 
indices. Thus, the present results provide useful information for the development of 
polyester based drug delivery systems. 
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Biodegradable polymers are inter-
esting materials in drug delivery as 
they are eliminated from the body 
without a second operation to remove 
them. In this study novel biodegrad-
able polymers, 2,2-bis(2-oxazoline) 
linked poly(ε-caprolactone) (PCL-O) 
and pegylated poly(lactic acid) linked 
with biotin (biotin-PEG-PLA), were 
developed for controlled and targeted 
pharmaceutical applications. Results 
indicate that PCL-O polymers are 
biocompatible and safe materials dis-
playing enzyme sensitive surface ero-
sion and biotinylated PLA-PEG nano-
particles enhance cancer therapy.
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